US20220184128A1 - Method for producing car gene-introduced nk cells and use thereof - Google Patents
Method for producing car gene-introduced nk cells and use thereof Download PDFInfo
- Publication number
- US20220184128A1 US20220184128A1 US17/598,916 US202017598916A US2022184128A1 US 20220184128 A1 US20220184128 A1 US 20220184128A1 US 202017598916 A US202017598916 A US 202017598916A US 2022184128 A1 US2022184128 A1 US 2022184128A1
- Authority
- US
- United States
- Prior art keywords
- cells
- cancer
- car
- ink
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000822 natural killer cell Anatomy 0.000 title claims abstract description 44
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 28
- 210000004027 cell Anatomy 0.000 claims abstract description 343
- 230000008672 reprogramming Effects 0.000 claims abstract description 92
- 238000000034 method Methods 0.000 claims abstract description 88
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 77
- 201000011510 cancer Diseases 0.000 claims abstract description 67
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 46
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 101150058049 car gene Proteins 0.000 claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 24
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 19
- 238000002659 cell therapy Methods 0.000 claims abstract description 14
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 39
- 102000004127 Cytokines Human genes 0.000 claims description 24
- 108090000695 Cytokines Proteins 0.000 claims description 24
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims description 24
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 24
- 238000012258 culturing Methods 0.000 claims description 23
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 20
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 20
- 102000003735 Mesothelin Human genes 0.000 claims description 20
- 108090000015 Mesothelin Proteins 0.000 claims description 20
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 19
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 19
- 239000003112 inhibitor Substances 0.000 claims description 18
- 239000003102 growth factor Substances 0.000 claims description 17
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims description 16
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 claims description 15
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 claims description 15
- -1 Asc11 Proteins 0.000 claims description 15
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 15
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 15
- 230000014509 gene expression Effects 0.000 claims description 15
- 230000003834 intracellular effect Effects 0.000 claims description 13
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 12
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 claims description 12
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims description 12
- 206010009944 Colon cancer Diseases 0.000 claims description 11
- 102000013462 Interleukin-12 Human genes 0.000 claims description 11
- 108010065805 Interleukin-12 Proteins 0.000 claims description 11
- LKTNEXPODAWWFM-UHFFFAOYSA-N 2-methyl-N-[2-methyl-4-(2-methylphenyl)azophenyl]-3-pyrazolecarboxamide Chemical compound CC1=CC=CC=C1N=NC(C=C1C)=CC=C1NC(=O)C1=CC=NN1C LKTNEXPODAWWFM-UHFFFAOYSA-N 0.000 claims description 10
- 108010043121 Green Fluorescent Proteins Proteins 0.000 claims description 10
- 102000004144 Green Fluorescent Proteins Human genes 0.000 claims description 10
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 10
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 10
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 10
- 239000005090 green fluorescent protein Substances 0.000 claims description 10
- 102000003812 Interleukin-15 Human genes 0.000 claims description 9
- 108090000172 Interleukin-15 Proteins 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 210000000130 stem cell Anatomy 0.000 claims description 9
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 102000015696 Interleukins Human genes 0.000 claims description 8
- 108010063738 Interleukins Proteins 0.000 claims description 8
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 8
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 201000005787 hematologic cancer Diseases 0.000 claims description 8
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 8
- 201000005202 lung cancer Diseases 0.000 claims description 8
- 208000020816 lung neoplasm Diseases 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 8
- 108090001005 Interleukin-6 Proteins 0.000 claims description 7
- 102000004889 Interleukin-6 Human genes 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 6
- 101100239628 Danio rerio myca gene Proteins 0.000 claims description 6
- 102000003810 Interleukin-18 Human genes 0.000 claims description 6
- 108090000171 Interleukin-18 Proteins 0.000 claims description 6
- 108010002386 Interleukin-3 Proteins 0.000 claims description 6
- 102000000646 Interleukin-3 Human genes 0.000 claims description 6
- 108010002586 Interleukin-7 Proteins 0.000 claims description 6
- 102000000704 Interleukin-7 Human genes 0.000 claims description 6
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 claims description 6
- 101150039798 MYC gene Proteins 0.000 claims description 6
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 claims description 6
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 claims description 6
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 101100459258 Xenopus laevis myc-a gene Proteins 0.000 claims description 6
- 108010074108 interleukin-21 Proteins 0.000 claims description 6
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 claims description 5
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 claims description 5
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 claims description 5
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 4
- 206010000830 Acute leukaemia Diseases 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 3
- 206010018338 Glioma Diseases 0.000 claims description 3
- 108010073807 IgG Receptors Proteins 0.000 claims description 3
- 102000009490 IgG Receptors Human genes 0.000 claims description 3
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 208000000172 Medulloblastoma Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 208000007541 Preleukemia Diseases 0.000 claims description 3
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 201000009036 biliary tract cancer Diseases 0.000 claims description 3
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 3
- 208000024207 chronic leukemia Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 208000003747 lymphoid leukemia Diseases 0.000 claims description 3
- 206010038038 rectal cancer Diseases 0.000 claims description 3
- 201000001275 rectum cancer Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 101150026563 NR4A2 gene Proteins 0.000 claims description 2
- 101150086694 SLC22A3 gene Proteins 0.000 claims description 2
- 201000006491 bone marrow cancer Diseases 0.000 claims description 2
- 101150111214 lin-28 gene Proteins 0.000 claims description 2
- 101150093695 pitx3 gene Proteins 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 230000005880 cancer cell killing Effects 0.000 abstract description 17
- 230000004069 differentiation Effects 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 14
- 210000004263 induced pluripotent stem cell Anatomy 0.000 abstract description 11
- 238000005516 engineering process Methods 0.000 abstract description 6
- 230000000670 limiting effect Effects 0.000 abstract description 2
- 239000002609 medium Substances 0.000 description 80
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 32
- 239000013598 vector Substances 0.000 description 27
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 20
- 239000012091 fetal bovine serum Substances 0.000 description 17
- 229930182555 Penicillin Natural products 0.000 description 16
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 16
- 229940049954 penicillin Drugs 0.000 description 16
- 229960005322 streptomycin Drugs 0.000 description 16
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- 239000003814 drug Substances 0.000 description 13
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 102100037850 Interferon gamma Human genes 0.000 description 12
- 108010074328 Interferon-gamma Proteins 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 11
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 238000006243 chemical reaction Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 241000713666 Lentivirus Species 0.000 description 8
- 238000003501 co-culture Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 101000716729 Homo sapiens Kit ligand Proteins 0.000 description 7
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 102000049850 human FLT3 Human genes 0.000 description 7
- 102000055151 human KITLG Human genes 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 6
- 230000001093 anti-cancer Effects 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 102000056003 human IL15 Human genes 0.000 description 6
- 102000040430 polynucleotide Human genes 0.000 description 6
- 108091033319 polynucleotide Proteins 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 5
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 102000043959 human IL18 Human genes 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 4
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 4
- 102100030703 Interleukin-22 Human genes 0.000 description 4
- 241000711408 Murine respirovirus Species 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 102000052611 human IL6 Human genes 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229960002378 oftasceine Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 3
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 206010052015 cytokine release syndrome Diseases 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000032459 dedifferentiation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 210000001671 embryonic stem cell Anatomy 0.000 description 3
- 102000055276 human IL3 Human genes 0.000 description 3
- 102000052622 human IL7 Human genes 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000015788 innate immune response Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- CRDNMYFJWFXOCH-YPKPFQOOSA-N (3z)-3-(3-oxo-1h-indol-2-ylidene)-1h-indol-2-one Chemical compound N/1C2=CC=CC=C2C(=O)C\1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-YPKPFQOOSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical compound N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 102100038077 CD226 antigen Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010008951 Chemokine CXCL12 Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102400001368 Epidermal growth factor Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000884298 Homo sapiens CD226 antigen Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000713333 Mouse mammary tumor virus Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000713896 Spleen necrosis virus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108700012411 TNFSF10 Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 2
- 102000055228 human IL5 Human genes 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- ZOAMBXDOGPRZLP-UHFFFAOYSA-N indole-3-acetamide Chemical compound C1=CC=C2C(CC(=O)N)=CNC2=C1 ZOAMBXDOGPRZLP-UHFFFAOYSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229960003130 interferon gamma Drugs 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 210000001778 pluripotent stem cell Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000004445 quantitative analysis Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- UXFNAATUJSSAHF-SZWANQOLSA-N (2r)-2-[(2e,7e,9e)-13-(furan-3-yl)-2,6,10-trimethyltrideca-2,7,9-trienyl]-3-hydroxy-4-methyl-2h-furan-5-one Chemical compound C1=COC=C1CCCC(/C)=C/C=C/C(C)CC\C=C(/C)C[C@H]1OC(=O)C(C)=C1O UXFNAATUJSSAHF-SZWANQOLSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- JLHWBVQBEGDSEZ-LFOOZZFTSA-N (4s)-5-[[(2s)-1-[(2s)-2-[(2s)-2-[[(2s)-1-[(2s)-2-[(2s)-2-[[(2s)-5-amino-1-[[(2s)-1-[(2s)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phosphonooxypropan-2-yl]amino]-1,5-dioxopentan-2-yl]carbamoyl]pyrrolidine-1-carbonyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]carbamoyl]p Chemical compound CCCCCCCCCCCCCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)N[C@@H](C)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](COP(O)(O)=O)C(=O)N2[C@@H](CCC2)C(N)=O)CCC1 JLHWBVQBEGDSEZ-LFOOZZFTSA-N 0.000 description 1
- PGPHHJBZEGSUNE-JYRVWZFOSA-N (5z)-2-anilino-5-(1,3-benzodioxol-5-ylmethylidene)-1h-imidazol-4-one Chemical compound N=1\C(=C/C=2C=C3OCOC3=CC=2)C(=O)NC=1NC1=CC=CC=C1 PGPHHJBZEGSUNE-JYRVWZFOSA-N 0.000 description 1
- NTSBZVCEIVPKBJ-UHFFFAOYSA-N 1-azakenpaullone Chemical compound C1C(=O)NC2=CC=CN=C2C2=C1C1=CC(Br)=CC=C1N2 NTSBZVCEIVPKBJ-UHFFFAOYSA-N 0.000 description 1
- JJAXTFSPCLZPIW-UHFFFAOYSA-N 2-(2,3,4-trihydroxyphenyl)chromen-4-one Chemical compound OC1=C(O)C(O)=CC=C1C1=CC(=O)C2=CC=CC=C2O1 JJAXTFSPCLZPIW-UHFFFAOYSA-N 0.000 description 1
- RCKYSTKYIVULEK-UHFFFAOYSA-N 2-methyl-5-[3-(4-methylsulfinylphenyl)-1-benzofuran-5-yl]-1,3,4-oxadiazole Chemical compound O1C(C)=NN=C1C1=CC=C(OC=C2C=3C=CC(=CC=3)S(C)=O)C2=C1 RCKYSTKYIVULEK-UHFFFAOYSA-N 0.000 description 1
- DWHVZCLBMTZRQM-UHFFFAOYSA-N 2H-pyrazolo[4,3-b]quinoxalin-3-amine Chemical compound C1=CC=CC2=NC3=C(N)NN=C3N=C21 DWHVZCLBMTZRQM-UHFFFAOYSA-N 0.000 description 1
- JCSGFHVFHSKIJH-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-4-(1-methyl-3-indolyl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C1=CC=C(Cl)C=C1Cl JCSGFHVFHSKIJH-UHFFFAOYSA-N 0.000 description 1
- RGTAEYDIDMGJLX-UHFFFAOYSA-N 3-(3-aminophenyl)-4-(1-methylindol-3-yl)pyrrole-2,5-dione Chemical compound C12=CC=CC=C2N(C)C=C1C(C(NC1=O)=O)=C1C1=CC=CC(N)=C1 RGTAEYDIDMGJLX-UHFFFAOYSA-N 0.000 description 1
- XRAMWNCMYJHGGH-UHFFFAOYSA-N 3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1h-indol-3-yl)pyrrole-2,5-dione;hydrochloride Chemical compound Cl.C12=CC=CC=C2N(CCCN(C)C)C=C1C1=C(C=2C3=CC=CC=C3NC=2)C(=O)NC1=O XRAMWNCMYJHGGH-UHFFFAOYSA-N 0.000 description 1
- ZKJAZFUFPPSFCO-UHFFFAOYSA-N 3-[2-(4-fluorophenyl)ethylamino]-1-methyl-4-(2-methyl-1H-indol-3-yl)pyrrole-2,5-dione Chemical compound CC=1NC2=CC=CC=C2C=1C=1C(=O)N(C)C(=O)C=1NCCC1=CC=C(F)C=C1 ZKJAZFUFPPSFCO-UHFFFAOYSA-N 0.000 description 1
- CLGRAWDGLMENOD-UHFFFAOYSA-N 3-[5-[4-(2-hydroxy-2-methylpropanoyl)piperazin-1-yl]-2-(trifluoromethyl)phenyl]-4-(1h-indol-3-yl)pyrrole-2,5-dione Chemical compound C1CN(C(=O)C(C)(O)C)CCN1C1=CC=C(C(F)(F)F)C(C=2C(NC(=O)C=2C=2C3=CC=CC=C3NC=2)=O)=C1 CLGRAWDGLMENOD-UHFFFAOYSA-N 0.000 description 1
- VPVLEBIVXZSOMQ-UHFFFAOYSA-N 3-[[6-(3-aminophenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-yl]oxy]phenol Chemical compound NC1=CC=CC(C=2NC3=NC=NC(OC=4C=C(O)C=CC=4)=C3C=2)=C1 VPVLEBIVXZSOMQ-UHFFFAOYSA-N 0.000 description 1
- XFYYQDHEDOXWGA-UHFFFAOYSA-N 4-[(5-bromopyridin-2-yl)amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC1=CC=C(Br)C=N1 XFYYQDHEDOXWGA-UHFFFAOYSA-N 0.000 description 1
- VXWVFZFZYXOBTA-UHFFFAOYSA-N 5-bromo-1h-indole Chemical compound BrC1=CC=C2NC=CC2=C1 VXWVFZFZYXOBTA-UHFFFAOYSA-N 0.000 description 1
- ULVWJFBHQIXEPE-UHFFFAOYSA-N 5-ethyl-7,8-dimethoxypyrrolo[3,4-c]isoquinoline-1,3-dione Chemical compound C12=CC(OC)=C(OC)C=C2C(CC)=NC2=C1C(=O)NC2=O ULVWJFBHQIXEPE-UHFFFAOYSA-N 0.000 description 1
- NDFXSHIIGXVOKT-UHFFFAOYSA-N 6-n-[2-[[4-(2,4-dichlorophenyl)-5-(1h-imidazol-2-yl)pyrimidin-2-yl]amino]ethyl]-3-nitropyridine-2,6-diamine Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(C=3NC=CN=3)=CN=2)C=2C(=CC(Cl)=CC=2)Cl)=C1 NDFXSHIIGXVOKT-UHFFFAOYSA-N 0.000 description 1
- PRIGRJPRGZCFAS-UHFFFAOYSA-N 6-phenyl[5h]pyrrolo[2,3-b]pyrazine Chemical compound N1C2=NC=CN=C2C(CCCC)=C1C1=CC=C(O)C=C1 PRIGRJPRGZCFAS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- BLTVBQXJFVRPFK-UHFFFAOYSA-N AZD1080 Chemical compound OC=1NC2=CC=C(C#N)C=C2C=1C(N=C1)=CC=C1CN1CCOCC1 BLTVBQXJFVRPFK-UHFFFAOYSA-N 0.000 description 1
- FHCSBLWRGCOVPT-UHFFFAOYSA-N AZD2858 Chemical compound C1CN(C)CCN1S(=O)(=O)C1=CC=C(C=2N=C(C(N)=NC=2)C(=O)NC=2C=NC=CC=2)C=C1 FHCSBLWRGCOVPT-UHFFFAOYSA-N 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- DQYBRTASHMYDJG-UHFFFAOYSA-N Bisindolylmaleimide Chemical compound C1=CC=C2C(C=3C(=O)NC(C=3C=3C4=CC=CC=C4NC=3)=O)=CNC2=C1 DQYBRTASHMYDJG-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- MDZCSIDIPDZWKL-UHFFFAOYSA-N CHIR-98014 Chemical compound C1=C([N+]([O-])=O)C(N)=NC(NCCNC=2N=C(C(=CN=2)N2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1 MDZCSIDIPDZWKL-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- CRDNMYFJWFXOCH-BUHFOSPRSA-N Couroupitine B Natural products N\1C2=CC=CC=C2C(=O)C/1=C1/C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-BUHFOSPRSA-N 0.000 description 1
- 208000009798 Craniopharyngioma Diseases 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 208000001258 Hemangiosarcoma Diseases 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 description 1
- 101000958041 Homo sapiens Musculin Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003815 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 102000000743 Interleukin-5 Human genes 0.000 description 1
- HRJWTAWVFDCTGO-UHFFFAOYSA-N LY-2090314 Chemical compound C1CN(C=23)C=C(C=4C(NC(=O)C=4C=4N5C=CC=CC5=NC=4)=O)C3=CC(F)=CC=2CN1C(=O)N1CCCCC1 HRJWTAWVFDCTGO-UHFFFAOYSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 206010025219 Lymphangioma Diseases 0.000 description 1
- 208000009018 Medullary thyroid cancer Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010063250 N-myristoyl-glycyl-lysyl-glutamyl-alanyl-prolyl-prolyl-alanyl-prolyl-prolyl-glutaminyl-phosphoseryl-proline Proteins 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCEPTSRBSLJCSK-UHFFFAOYSA-N Palinurin Natural products CC(CCC=C(/C)C1OC(=O)C(=C1O)C)C=CC=C(/C)CCCc2cocc2 ZCEPTSRBSLJCSK-UHFFFAOYSA-N 0.000 description 1
- 206010033701 Papillary thyroid cancer Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- PQCXVIPXISBFPN-UHFFFAOYSA-N SB 415286 Chemical compound C1=C(Cl)C(O)=CC=C1NC1=C(C=2C(=CC=CC=2)[N+]([O-])=O)C(=O)NC1=O PQCXVIPXISBFPN-UHFFFAOYSA-N 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- JDSJDASOXWCHPN-UHFFFAOYSA-N TDZD-8 Chemical compound O=C1N(C)SC(=O)N1CC1=CC=CC=C1 JDSJDASOXWCHPN-UHFFFAOYSA-N 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 208000014070 Vestibular schwannoma Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- HUDSYNWJCPDHLL-CJLVFECKSA-N [(E)-[2-(6-bromo-2-hydroxy-1H-indol-3-yl)indol-3-ylidene]amino] acetate Chemical compound CC(=O)O\N=C1\C(=Nc2ccccc12)c1c(O)[nH]c2cc(Br)ccc12 HUDSYNWJCPDHLL-CJLVFECKSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 208000004064 acoustic neuroma Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 108010023082 activin A Proteins 0.000 description 1
- 101150063416 add gene Proteins 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- OLUKILHGKRVDCT-UHFFFAOYSA-N alsterpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC([N+](=O)[O-])=CC=C1N2 OLUKILHGKRVDCT-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000004668 avian leukosis Diseases 0.000 description 1
- 208000005266 avian sarcoma Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- MGQSIUXWCFOENX-UHFFFAOYSA-N cazpaullone Chemical compound C12=NC=CC=C2NC(=O)CC2=C1NC1=CC=C(C#N)C=C21 MGQSIUXWCFOENX-UHFFFAOYSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- FQCPPVRJPILDIK-UHFFFAOYSA-N chembl126077 Chemical compound N1C2=CC=CC=C2C(N=O)=C1C1=C(O)NC2=CC=CC=C21 FQCPPVRJPILDIK-UHFFFAOYSA-N 0.000 description 1
- PIDGGJYETVQYET-UHFFFAOYSA-N chembl173171 Chemical compound C12=CC=C(Br)C=C2N(C)C(O)=C1C1=C(N=O)C2=CC=CC=C2N1 PIDGGJYETVQYET-UHFFFAOYSA-N 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013601 cosmid vector Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 1
- 208000037828 epithelial carcinoma Diseases 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011124 ex vivo culture Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 201000002222 hemangioblastoma Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 102000046949 human MSC Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- ZXRCAYWYTOIRQS-UHFFFAOYSA-N hydron;phenol;chloride Chemical compound Cl.OC1=CC=CC=C1 ZXRCAYWYTOIRQS-UHFFFAOYSA-N 0.000 description 1
- QPCBNXNDVYOBIP-WHFBIAKZSA-N hymenialdisine Chemical compound NC1=NC(=O)C([C@@H]2[C@@H]3C=C(Br)N=C3C(=O)NCC2)=N1 QPCBNXNDVYOBIP-WHFBIAKZSA-N 0.000 description 1
- ATBAETXFFCOZOY-UHFFFAOYSA-N hymenialdisine Natural products N1C(N)=NC(=O)C1=C1C(C=C(Br)N2)=C2C(=O)NCC1 ATBAETXFFCOZOY-UHFFFAOYSA-N 0.000 description 1
- KHJREOQCERRAME-UHFFFAOYSA-N hymenidine Natural products N1C(N)=NC(C=CCNC(=O)C=2NC=C(Br)C=2)=C1 KHJREOQCERRAME-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- CRDNMYFJWFXOCH-UHFFFAOYSA-N isoindigotin Natural products N1C2=CC=CC=C2C(=O)C1=C1C2=CC=CC=C2NC1=O CRDNMYFJWFXOCH-UHFFFAOYSA-N 0.000 description 1
- QQUXFYAWXPMDOE-UHFFFAOYSA-N kenpaullone Chemical compound C1C(=O)NC2=CC=CC=C2C2=C1C1=CC(Br)=CC=C1N2 QQUXFYAWXPMDOE-UHFFFAOYSA-N 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 208000015534 lymphangioendothelioma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- FUCSLKWLLSEMDQ-MKYGIPPKSA-N manzamine A Chemical compound C1C\C=C/CCCCN2CC[C@H]3C(C=4C=5NC6=CC=CC=C6C=5C=CN=4)=C[C@]1(O)[C@@H]1N4CCCC\C=C/[C@H]4C[C@@]13C2 FUCSLKWLLSEMDQ-MKYGIPPKSA-N 0.000 description 1
- FUCSLKWLLSEMDQ-UHFFFAOYSA-N manzamine A hydrochloride Natural products C1CC=CCCCCN2CCC3C(C=4C=5NC6=CC=CC=C6C=5C=CN=4)=CC1(O)C1N4CCCCC=CC4CC13C2 FUCSLKWLLSEMDQ-UHFFFAOYSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000023356 medullary thyroid gland carcinoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229930188764 meridianine Natural products 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- SAWVGDJBSPLRRB-UHFFFAOYSA-N methanesulfonic acid;3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate Chemical compound CS(O)(=O)=O.C12=CC=CC=C2N(C)C=C1C1=C(C=2C3=CC=CC=C3N(CCCSC(N)=N)C=2)C(=O)NC1=O SAWVGDJBSPLRRB-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 208000001611 myxosarcoma Diseases 0.000 description 1
- JYCNWQGNEJYDQS-UHFFFAOYSA-N n-(3-chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine Chemical compound C1=C(Cl)C(C)=CC=C1NC1=NN=C(C=2C=CC(=CC=2)[N+]([O-])=O)O1 JYCNWQGNEJYDQS-UHFFFAOYSA-N 0.000 description 1
- YAEMHJKFIIIULI-UHFFFAOYSA-N n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea Chemical compound C1=CC(OC)=CC=C1CNC(=O)NC1=NC=C([N+]([O-])=O)S1 YAEMHJKFIIIULI-UHFFFAOYSA-N 0.000 description 1
- KHJREOQCERRAME-OWOJBTEDSA-N n-[(e)-3-(2-amino-1h-imidazol-5-yl)prop-2-enyl]-4-bromo-1h-pyrrole-2-carboxamide Chemical compound N1C(N)=NC=C1\C=C\CNC(=O)C1=CC(Br)=CN1 KHJREOQCERRAME-OWOJBTEDSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 208000020943 pineal parenchymal cell neoplasm Diseases 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 101150107865 prf1 gene Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 201000010965 sweat gland carcinoma Diseases 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 1
- PMJIHLSCWIDGMD-UHFFFAOYSA-N tideglusib Chemical compound O=C1SN(C=2C3=CC=CC=C3C=CC=2)C(=O)N1CC1=CC=CC=C1 PMJIHLSCWIDGMD-UHFFFAOYSA-N 0.000 description 1
- 229950005284 tideglusib Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OTLUUQOHVRZSKD-UHFFFAOYSA-N tricantin Natural products CC(CCC=C(/C)C1OC(=O)C(=O)C1=O)C=CC=C(/C)CCCc2cocc2 OTLUUQOHVRZSKD-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- PBYZMCDFOULPGH-UHFFFAOYSA-N tungstate Chemical compound [O-][W]([O-])(=O)=O PBYZMCDFOULPGH-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464403—Receptors for growth factors
- A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464466—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/464468—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/54—Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2303—Interleukin-3 (IL-3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2315—Interleukin-15 (IL-15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2318—Interleukin-18 (IL-18)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2321—Interleukin-21 (IL-21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/602—Sox-2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/603—Oct-3/4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/604—Klf-4
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/60—Transcription factors
- C12N2501/606—Transcription factors c-Myc
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases (EC 2.)
- C12N2501/727—Kinases (EC 2.7.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
- C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18811—Sendai virus
- C12N2760/18841—Use of virus, viral particle or viral elements as a vector
- C12N2760/18843—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Definitions
- the present invention relates to a method for producing induced natural killer (iNK) cells into which a chimeric antigen receptor (CAR) gene encoding a CAR is introduced, iNK cells produced by the method, and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, including the iNK cells.
- iNK induced natural killer
- CAR chimeric antigen receptor
- NK (natural killer) cells are key innate immune cells that perform the body's primary defense (innate immunity) function by immediately recognizing and eliminating infections of viruses, bacteria and parasites, and abnormal autologous cells (especially cancer cells).
- T cells which recognize target cells by expressing antigen-specific receptors
- NK cells perceive abnormal changes in target cells (especially cancer cells), such as balance of inhibitory or activating receptors, i.e., killer immunoglobulin receptors (KIR), natural cytotoxicity receptors (NCR), DNAM-1 (DNAX accessory molecule-1), and NKG2D (NK group 2 member D, and loss of surface MHC (major histocompatibility complex) class I antigen, without antigen specificity and human leukocyte antigen (HLA) matching, and have contact-dependent cytotoxicity.
- KIR killer immunoglobulin receptors
- NCR natural cytotoxicity receptors
- DNAM-1 DNAX accessory molecule-1
- NKG2D NK group 2 member D
- NK cells can kill cancer cells by directly mediating target cancer cell apoptosis through secretion of cytokines, such as perforin (Prf1), granzyme B (GzmB), interferon- ⁇ (IFN- ⁇ ), interleukin (tumor necrosis factor- ⁇ ; TNF- ⁇ ), etc., and activation of apoptosis-inducing receptors (Fas, tumor necrosis factor-related apoptosis-inducing ligand; TRAIL).
- cytokines such as perforin (Prf1), granzyme B (GzmB), interferon- ⁇ (IFN- ⁇ ), interleukin (tumor necrosis factor- ⁇ ; TNF- ⁇ ), etc.
- IFN- ⁇ interferon- ⁇
- TNF- ⁇ interleukin
- TRAIL apoptosis-inducing receptors
- NK cells that express Fc receptor-FcR ⁇ IIIa can effectively eliminate cancer cells directly or indirectly by inducing acquired immunity as well as innate immunity, such as mediating antibody-dependent cellular cytotoxicity (ADCC).
- ADCC antibody-dependent cellular cytotoxicity
- NK cells do not cause side effects such as graft-versus-host disease (GVHD), and thus have gained attention as a safe cell source that can be used for the development of not only autologous but also allogeneic anticancer immune cell therapeutics.
- GVHD graft-versus-host disease
- human NK cells are produced by isolating and proliferating a small amount of cells present in the human body [peripheral blood, bone marrow, umbilical cord blood, etc.] through a primary culture method, or can be obtained multidimensionally from stem cells having the ability to differentiate into NK cells [hematopoietic stem cells (HSCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs)] through differentiation induction culture.
- HSCs hematopoietic stem cells
- ESCs embryonic stem cells
- iPSCs induced pluripotent stem cells
- CAR-T cells which are produced by introducing a cancer cell target chimeric antigen receptor (CAR) gene as a method for promoting specificity and activation for target cancer cells and consequently enhancing the efficacy of anticancer treatment, have an enhanced anticancer effect in the treatment of blood cancer, and thus have received much interest in the development of CAR-immune cell therapeutics.
- CRS cytokine release syndrome
- IFN interferon
- TNF tumor necrosis factor
- IL-6 factors secreted by CAR-T cells is recognized as a serious problem that needs to be solved.
- CAR-T cells are known to inhibit cancer cell cytotoxicity by the immune checkpoint protein PD (programmed death ligand)-1, etc. in the tumor microenvironment (TME) of solid tumors, and accordingly, there is a need for technology development to improve the efficacy of solid cancer treatments.
- PD programmed death ligand
- NK cells secrete IL-3 and granulocyte-macrophage colony-stimulating factor, they are less likely to cause CRS [K. Rezvani, R. Rouce, E. Liu et al., Engineering Natural Killer Cells for Cancer Immunotherapy, Mol. Ther., 25 (2017), pp. 1769-1781]. Additionally, the level of PD-1 secreted by NK cells is substantially low, and almost no immunosuppression is induced, and also, it is known that NK cells enable migration of dendritic cells to tumors, thereby enhancing anti-PD-1 immunotherapy [K. C. Barry, J. Hsu, M. L. Broz, et al.
- a Natural Killer-dendritic Cell Axis Defines Checkpoint Therapy-responsive Tumor Microenvironments, Nat. Med., 24 (2016), pp. 1178-1191], and thus, the excellence of CAR-NK development has been demonstrated. Further, it was confirmed from the results of preclinical and clinical trials for CAR-NK cell therapy that NK cells can effectively remove blood cancer and solid cancer cells [E. L. Siegler, Y. Zhu, P. Wang, et al. Off-the-shelf CAR-NK Cells for Cancer Immunotherapy, Cell Stem Cell, 23 (2016), pp. 160-161], and thus have been recognized to have the potential to be developed as anticancer immune cell therapeutics in a wide range, including for solid cancers.
- a method for introducing a CAR gene specific for a cancer antigen into a single NK cell line NK-92, iPSC, etc.
- NK-92, iPSC, etc. a single NK cell line
- the most used primary cultured NK-92 cells are cells derived from patients with malignant non-Hodgkin's lymphoma and have the potential to induce secondary tumorigenesis and EB (Epstein-Barr) virus sensitivity after injection.
- a lethal irradiation process is essential before clinical application, but this process shortens the in vivo survival time of CAR-NK-92 cells, and consequently, the anticancer effect is reduced.
- the method of producing NK cells by introducing a CAR gene into induced pluripotent stem cells (iPSCs) and inducing differentiation essentially requires not only the CAR-iPSCs process, and isolation and amplification process, but also a complex differentiation process that involves much time and cost, and carries the possibility of tumor formation, and thus, it is essential to develop a technology that can secure and maintain safety.
- the present inventors have made extensive efforts to develop a method for efficiently producing CAR-NK cells, and as a result, they have developed a CAR-NK cell-specific reprogramming medium and reprogramming culture conditions, and confirmed that CAR-NK cells can be produced from human somatic cells by a method that does not require a differentiation process without limiting the initial cell resources, and accordingly, the produced CAR-NK cells exhibit an excellent cancer cell killing ability and thus can be applied to the prevention or treatment of cancer, thereby completing the present invention.
- a reprogramming factor and a CAR chimeric antigen receptor
- the method according to the present invention can produce iNK cells, into which a CAR gene is introduced, from the isolated cells without a differentiation process through direct reprogramming, thereby producing CAR-NK cells with an enhanced cancer cell killing function with high efficiency without limitation of the initial cells, and has an effect of reducing cost and time by simplifying the production process.
- NK cells can be produced without passing through induced pluripotent stem cells produced through a conventional reprogramming technique, there is an excellent NK cell production effect which is enhanced and distinguished in terms of safety.
- the CAR gene-introduced iNK cells produced by the above method have an excellent cancer cell killing ability, and thus can be effectively utilized as a cell therapy composition or a pharmaceutical composition for preventing or treating cancer.
- FIG. 1 shows a diagram showing the constitutional domains of four CAR genes.
- FIG. 2 is a schematic diagram showing a method for producing CAR-iNK by direct somatic cell reprogramming and CAR gene introduction.
- FIG. 3 is a result confirming CD19-CAR-iNK cells produced from PBMC.
- FIG. 4 is a result confirming MSLN-CAR-iNK cells produced from PBMC.
- FIG. 5 is a result confirming HER2-CAR-iNK cells produced from PBMC.
- FIG. 6 shows a result confirming the CD19-CAR-iNK cells produced according to the introduction period of CAR-expressing lentivirus (day 0, day 14, day 24), and (B) shows a result confirming the insertion of the CD19-CAR gene in the iNK cells produced from PBMC.
- FIG. 7 is a result confirming the CAR-iNK production efficiency according to the composition or incubation time of the CAR-iNK first medium and third medium.
- FIG. 8 is a result confirming the frequency of CD107a-expressing cells during co-culture of the produced CD19-CAR-iNK cells and cancer cells.
- FIG. 9 is a result confirming the frequency of CD107a-expressing cells during co-culture of the produced CD19-CAR-iNK cells and cancer cells.
- FIG. 10 is a result confirming the frequency of CD107a-expressing cells during co-culture of the produced MSLN-CAR-iNK cells and cancer cells.
- FIG. 11 is a result confirming the frequency of CD107a-expressing cells during co-culture of the produced HER2-CAR-iNK cells and cancer cells.
- FIG. 12 is a result confirming the frequency of IFN-gamma-expressing cells during co-culture of the produced CD19-CAR-iNK cells and cancer cells.
- FIG. 13 is a result confirming the frequency of IFN-gamma-expressing cells during co-culture of the produced CD19-CAR-iNK cells and cancer cells.
- FIG. 14 is a result confirming the frequency of IFN-gamma-expressing cells during co-culture of the produced MSLN-CAR-iNK cells and cancer cells.
- FIG. 15 is a result confirming the frequency of IFN-gamma-expressing cells during co-culture of the produced HER2-CAR-iNK cells and cancer cells.
- FIG. 16 is a result confirming the cancer cell killing ability of the produced CD19-CAR-iNK cells.
- FIG. 17 is a result confirming the cancer cell killing ability of the produced MSLN-CAR-iNK cells.
- FIG. 18 is a result confirming the cancer cell killing ability of the produced HER2-CAR-iNK cells.
- FIG. 19 is a result confirming the tumor growth inhibitory effect of MSLN-CAR-iNK cells in a pancreatic cancer cell xenograft mouse animal model.
- one aspect of the present invention provides a method for producing CAR-iNK (induced natural killer) cells, including: culturing isolated cells, into which a reprogramming factor and a CAR (chimeric antigen receptor) gene are introduced, sequentially in a) a first medium containing growth factors, cytokines, and a GSK3 ⁇ (glycogen synthase kinase 3 beta) inhibitor; b) a second medium containing growth factors, cytokines, and an AHR (aryl hydrocarbon receptor) antagonist; and c) a third medium containing cytokines, a GSK3 ⁇ inhibitor, and an AHR antagonist, and thereby directly reprogramming into NK cells.
- a reprogramming factor and a CAR (chimeric antigen receptor) gene sequentially in a) a first medium containing growth factors, cytokines, and a GSK3 ⁇ (glycogen synthase kinase 3 beta) inhibitor
- NK naturally killer cell
- innate immunity first defense
- cancer cells abnormal autologous cells
- NK cells have been proven to be effective in preventing the occurrence, proliferation, metastasis, and recurrence of various types of cancers including not only blood cancer but solid cancers, and thus have received attention as a useful cellular resource for anticancer therapeutics and relapse inhibitors.
- Efforts to develop NK cells isolated and cultured from the human body and NK cells differentiated from stem cells as anticancer immune cell therapeutics are rapidly increasing, but low NK production efficiency and anticancer treatment efficacy are still recognized as problems to be overcome.
- NK (CAR-NK) cells expressing a chimeric antigen receptor (CAR) specific to various cancer antigens were produced, and accordingly, studies are being actively conducted to investigate the enhancement of cancer cell killing ability and its therapeutic efficacy.
- CAR-NK cells As a method for producing the CAR-NK cells, a method of introducing cells into a single NK cell line (NK-92, iPSCs, etc.) that is relatively easy to culture and proliferate is mainly used, but low production efficiency, a complicated process, and safety issues (possibility of tumor formation, etc.) have been recognized as problems to be overcome.
- the present inventors have attempted to produce CAR-NK cells using a method that is applicable to various human somatic cells that are easy to collect under ex vivo culture conditions and does not require a differentiation process, and a result, they have identified for the first time a method for directly inducing and producing CAR-NK cells from isolated human somatic cells through direct reprogramming.
- CAR-iNK CAR-induced natural killer cell
- NK natural killer
- the term “reprogramming” refers to a method of converting a lineage into a target cell having completely different characteristics by controlling the global gene expression pattern of a specific cell.
- Reprogramming may include dedifferentiation of cells, direct reprogramming or direct conversion, or direct trans-differentiation, but is not limited thereto.
- the reprogramming may be performed by introducing a vector containing a foreign gene or DNA into a cell.
- transformation refers to the change of a cell to a different state
- differentiation refers to a phenomenon in which daughter cells produced by cell division acquire a function different from that of the original parent cell
- conversion and “differentiation” can be used interchangeably with “induction”.
- NK cells which are target cells
- conventional reprogramming techniques 1) induced pluripotent stem cells were produced from isolated somatic cells; 2) hematopoietic stem (progenitor) cells, the intermediate, were subjected to primary differentiation and production from induced pluripotent stem cells; 3) and subsequently, NK cells, which are target cells, were subjected to secondary differentiation and production from differentiated stem (progenitor) cells.
- the conventional technique has the disadvantages of low production efficiency and high time and cost consumption, because it has to sequentially go through a complex culture process.
- NK cells are produced via induced pluripotent stem cells with pluripotency, the remaining undifferentiated cells have the potential to form tumors, and thus safety is an important issue to be verified.
- the present invention produces NK cells, which are the target cells, directly from isolated somatic cells through direct reprogramming, thereby providing reduced production time and cost, and excellent efficiency and safety, and thus can be distinguished from the prior art and can provide an alternative that can overcome the problems.
- the direct reprogramming may be used interchangeably with direct dedifferentiation, direct differentiation, direct conversion, direct cross-differentiation, cross-differentiation, etc., and as used herein, the direct reprogramming may mean direct dedifferentiation or cross-differentiation into NK cells from isolated somatic cells, but is not limited thereto.
- the term “differentiated cells” refers to a state in which cells with specialized structures or functions, that is, cells, tissues, etc. of living organisms, have changed into a form and function suitable for performing the role assigned thereto.
- the differentiated cells broadly refer to ectodermal, mesodermal, and endodermal cells derived from pluripotent stem cells such as embryonic stem cells, and narrowly to red blood cells, white blood cells, platelets, etc. derived from hematopoietic stem cells.
- the “lineage-conversion cell” is a cell which is converted to a cell type with different lineage characteristics due to the change in the intrinsic lineage characteristics of the cell embryologically or artificially (e.g., reprogramming, etc.), thereby having the characteristics of a cell type that are completely different from the characteristics of the cell type before conversion.
- the lineage-conversion cell may be a target cell.
- non-NK lymphocyte cells in peripheral blood mononuclear cells may be converted to NK cells in a reprogramming medium, but are not limited thereto.
- the method may be performed by culturing isolated cells, into which a reprogramming factor and a CAR gene are introduced, sequentially in a) a first medium containing growth factors, cytokines, and a GSK3 ⁇ (glycogen synthase kinase 3 beta) inhibitor; b) a second medium containing growth factors, cytokines, and an AHR (aryl hydrocarbon receptor) antagonist; and c) a third medium containing cytokines, a GSK3 ⁇ inhibitor, and an AHR antagonist, and thereby directly reprogramming into NK cells.
- a first medium containing growth factors, cytokines, and a GSK3 ⁇ (glycogen synthase kinase 3 beta) inhibitor
- a third medium containing cytokines, a GSK3 ⁇ inhibitor, and an AHR antagonist, and thereby directly reprogramm
- isolated cells are not particularly limited, but specifically refer to cells whose lineage has already been specified, such as germ cells, somatic cells, or progenitor cells.
- the “somatic cells” refer to all cells in which differentiation constituting animals and plants has been completed except for germ cells.
- progenitor cells refer to a mother cell which does not express a differentiated character, but has a differentiation fate, if it has been found that a cell corresponding to its progeny expresses a certain differentiation character.
- nerve cells nerve cells
- nerve fibroblasts neurovascular stem cells
- myoblasts correspond to the precursor cell.
- the isolated cells may be cells derived from a human, but are not limited thereto, and cells derived from various individuals may also fall within the scope of the present invention.
- the isolated cells of the present invention may include both in vivo or ex vivo cells.
- the isolated cells may be somatic cells, and more specifically, somatic cells other than NK cells, but are not limited thereto.
- reprogramming factor refers to a gene (or polynucleotide) that can be introduced into a cell to induce reprogramming, or a protein encoded therefrom.
- the reprogramming factor may vary depending on the target cell to be obtained through reprogramming, and the type of cell before reprogramming.
- the reprogramming factor introduced into the isolated somatic cells may include any one or more selected from the group consisting of Lin28, Asc11, Pitx3, Nurr1, Lmx1a, Nanog, Oct4, Oct3, Sox2, Klf4, Myc, and a combination thereof, and specifically Oct4, Sox2, Klf4, and Myc, but is not limited thereto, and may include any factor known in the art as long as it is a reprogramming factor that can induce the isolated somatic cells into NK cells.
- the reprogramming using the reprogramming factor is the induction of conversion to a target cell by controlling the entire gene expression pattern of the cell, and the cell may be reprogrammed into a target cell having a gene expression pattern of a desired type of cell by introducing the reprogramming factor into the cell and culturing the same for a certain period of time.
- the “introduction of reprogramming factor” may be a method of administering a reprogramming factor to a culture solution of cells; a method of directly injecting a reprogramming factors into cells; a method of increasing the expression level of a reprogramming factor present in a cell; a method of transforming a cell with an expression vector containing a gene encoding a reprogramming factor; a method of modifying a gene sequence to increase the expression of a gene encoding a reprogramming factor; a method of introducing an exogenously expressed gene encoding a reprogramming factor; a method of treating a substance having an effect of inducing expression of the reprogramming factor; and a method of increasing the expression level of a reprogramming factor in a cell through a combination thereof, but is not limited thereto as long as it can increase the expression level of the reprogramming factor.
- the introduction of reprogramming factor may be inducing expression of a reprogramming factor depending on a desired time and conditions.
- the method of introducing a reprogramming factor into a cell may be a method of administering a reprogramming factor to a cell culture solution, or a method of transforming a cell with an expression vector containing a gene encoding a reprogramming factor, but this not limited.
- the method of directly injecting a reprogramming factor into a cell may be performed by selecting any method known in the art, but is not limited thereto, and may be performed by appropriately selecting from the methods using microinjection, electroporation, particle bombardment, direct muscle injection, an insulator, and a transposon.
- the term “vector” refers to a DNA construct containing the nucleotide sequence of a suitable regulatory sequence and the target protein or polypeptide so as to be able to express the target protein or polypeptide in a suitable host cell.
- the regulatory sequence may include a promoter, an operator, an initiation codon, a termination codon, a polyadenylation signal, an enhancer, etc.
- the vector of the present invention may include a signal sequence or a leader sequence for membrane targeting or secretion, in addition to the regulatory sequence, and can be prepared in various ways depending on the desired purpose.
- the promoter of the vector may be constitutive or inducible.
- the vector may include a selective marker for selecting a host cell containing the vector, and in the case of a replicable vector, may include a replication origin. Once transformed into a suitable host cell, the vector may replicate or function independently of the host genome, or may integrate into the genome thereof.
- the vector used in the present invention is not particularly limited as long as it is able to replicate in the host cell, and any vector known in the art may be used.
- Examples of the vector conventionally used may include natural or recombinant virus vector, episomal vector, plasmid vector, cosmid vector, etc.
- the virus vector may include vectors derived from retrovirus such as Sendai virus, lentivirus, HIV (human immunodeficiency virus, MLV (murine leukemia virus), ASLV (avian sarcoma/leukosis), SNV (spleen necrosis virus), RSV (Rous sarcoma virus), MMTV (mouse mammary tumor virus), etc., adenovirus, adeno-associated virus, herpes simplex virus, and more specifically, it may be an RNA-based virus vector, but is not limited thereto.
- retrovirus such as Sendai virus, lentivirus, HIV (human immunodeficiency virus, MLV (murine leukemia virus), ASLV (avian sarcoma/leukosis), SNV (spleen necrosis virus), RSV (Rous sarcoma virus), MMTV (mouse mammary tumor virus), etc.
- adenovirus adeno-associated virus
- herpes simplex virus
- the episomal vector is a non-viral non-insertable vector, and is known to have a property of expressing a gene included in the vector without being inserted into a chromosome. Accordingly, the cell containing the episomal vector may include both cases in which the episomal vector is inserted into the genome or is present in a cell without being inserted into the genome.
- operably linked refers to a functional linkage between a nucleic acid expression regulatory sequence and a nucleic acid sequence encoding a target protein so as to perform a general function.
- the operative linkage with the recombinant vector can be prepared using genetic recombination techniques well known in the art, and site-specific DNA cleavage and ligation are carried out using enzymes generally known in the art.
- CAR gene refers to a gene encoding a chimeric antigen receptor consisting of an extracellular domain, a transmembrane domain, and an intracellular domain including genes encoding the extracellular domain, the transmembrane domain, and the intracellular domain including an antibody domain (scFv).
- the CAR gene may be any one or more selected from the group consisting of a CD19-CAR1 gene or CD19-CAR2 gene including CD19 scFv, a MSLN-CAR gene including MSLN (mesothelin) scFv, and a HER2-CAR gene including HER2 (human epidermal growth factor receptor 2) scFv, but is not limited thereto.
- CAR target factors for solid tumors include EGFRvIII (Morgan R A, Hum Gene Ther. 2012; 23:1043-1053), MUC-1 (Wilkie S, J Immunol. 2008; 180:4901-4909), MAGE (Willemsen R A, Gene Ther. 2001; 8:1601-1608), CEA (Emtage P C, Clin Cancer Res. 2008; 14:8112-8122), PSMA, GD2, CA125, Her2 and MSLN, FAP, VEGFR (Kakarla S, Cancer J. 2014; 20:151-155), etc.
- the CD19 is the cluster of differentiation (CD) assigned with number 19 for identifying cell surface molecules according to the immunophenotype, and the CD19 refers to a marker of B lymphocytes.
- the CD19 is known to be expressed in most B-cell malignant cancer cells and thus provides an ideal target for these carcinomas.
- the CAR gene may be any one or more selected from the group consisting of:
- a CAR gene (CD19-CAR1 gene) including CD8 leader, CD19 scFv, CD8 hinge, CD8 transmembrane domain, and Fc- ⁇ receptor;
- a CAR gene (CD19-CAR2 gene) including CD8 leader, CD19 scFv, CD8 hinge, CD8 transmembrane domain, CD28 intracellular domain, CD3 ⁇ , and IRES (internal ribosome entry site);
- a CAR gene including CD8 leader, MSLN (mesothelin) scFv, CD8 hinge, CD8 transmembrane domain, CD28 intracellular domain, CD3 ⁇ , and IRE; and
- a CAR gene including CD8 leader, HER2 (human epidermal growth factor receptor 2) scFv, CD8 hinge, CD8 transmembrane domain, CD28 intracellular domain, CD3 ⁇ , and IRES, but is not limited thereto.
- the CD8 leader may include a nucleotide sequence of SEQ ID NO: 1, CD19 scFv may include a nucleotide sequence of SEQ ID NO: 2, MSLN scFv may include a nucleotide sequence of SEQ ID NO: 3, HER2 scFv may include a nucleotide sequence of SEQ ID NO: 4, CD8 hinge may include a nucleotide sequence of SEQ ID NO: 5, CD8 transmembrane domain may include a nucleotide sequence of SEQ ID NO: 6, Fc- ⁇ receptor may include a nucleotide sequence of SEQ ID NO: 7, CD28 intracellular domain may include a nucleotide sequence of SEQ ID NO: 8, CD3 ⁇ may include a nucleotide sequence of SEQ ID NO: 9, and the IRES inserted to clone the CAR gene into a vector constituting a double cistron may include a nucleotide sequence of SEQ ID NO: 10, but is not limited there
- the CAR gene may further include GFP (green fluorescent protein), but is not limited thereto.
- the GFP may include a nucleotide sequence of SEQ ID NO: 11, but is not limited thereto.
- nucleotide sequences of SEQ ID NO: 1 to SEQ ID NO: 11 can be confirmed from NCBI Genbank, a known database.
- the nucleotide sequences of SEQ ID NO: 1 to SEQ ID NO: 11 may include a nucleotide sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or more homology or identity with SEQ ID NO: 1 to SEQ ID NO: 11. Additionally, it is apparent that a nucleotide sequence in which a part of the sequence is deleted, modified, substituted, or added may be included within the scope of the present invention as long as the nucleotide sequence has such homology or identity and exhibits a function corresponding to the nucleotide sequences of SEQ ID NO: 1 to SEQ ID NO: 11.
- homology and identity refers to a degree of relatedness between two given amino acid sequences or nucleotide sequences, and may be expressed as a percentage. The terms homology and identity may often be used interchangeably with each other.
- sequence homology or identity of conserved polynucleotides or polypeptide may be determined by standard alignment algorithms and can be used with a default gap penalty established by the program being used. Substantially, homologous or identical sequences are generally expected to hybridize to all or at least about 50%, 60%, 70%, 80%, or 90% or more of the entire length of the sequences under moderate or high stringent conditions. Polynucleotides that contain degenerate codons instead of codons in hybridizing polynucleotides are also considered.
- the homology or identity of the polypeptide or polynucleotide sequences may be determined by, for example, BLAST algorithm by literature [see Karlin and Altschul, Pro. Natl. Acad. Sci. USA, 90, 5873(1993)], or FASTA by Pearson (see Methods Enzymol., 183, 63, 1990). Based on the algorithm BLAST, a program referred to as BLASTN or BLASTX has been developed (see: http://www.ncbi.nlm.nih.gov).
- any two amino add or polynucleotide sequences may be identified by comparing the sequences in a Southern hybridization experiment under stringent conditions as defined, and appropriate hybridization conditions defined are within the skill of the art, and may be determined by a method well known to those skilled in the art (for example, J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989; F. M. Ausubel et al., Current Protocols in Molecular Biology ).
- the CAR gene may be introduced into the cell in the same manner as the above-described method for introducing a reprogramming factor, and in particular, the reprogramming factor and the CAR gene may be introduced simultaneously or sequentially depending on a desired time and conditions.
- the lentivirus expressing CAR may be transformed into PBMC at the time of conversion into iNK or into cells at the time of reprogramming induction process by inoculating into a culture medium selected from the steps of culturing in the CAR-iNK first medium, CAR-iNK second medium, or CAR-iNK third medium, simultaneously with the reprogramming factor or after introduction of the reprogramming factor.
- the method according to the present invention is significant in that CAR-expressing NK cells can be produced by introducing the CAR gene and the reprogramming factor into isolated cells other than NK cells.
- the time of introducing the CAR gene can be determined as desired by those skilled in the art during the reprogramming culturing process.
- the time of introduction of the CAR gene that is, the time of inoculation of the CAR-expressing lentivirus may be carried out simultaneously with the reprogramming factor (day 0), or at the step of culturing in the CAR-iNK second medium (day 12) or the CAR-iNK third medium (day 24) after introduction of the reprogramming factor, but is not limited thereto ( FIGS. 2 and 6 ).
- the term “culture” means that the microorganism is grown under appropriately controlled environmental conditions.
- the culturing process of the present invention may be performed in a suitable culture medium and culture conditions known in the art. Such a culturing process may be easily adjusted for use by those skilled in the art according to the strain to be selected.
- the culture is a process of converting cells into which reprogramming factors and/or CAR genes have been introduced into target cells of another lineage.
- the composition of the first medium, the second medium, or the third medium for culturing the cells into which the gene is introduced is a composition suitable for conversion into target cells, and for example, may include growth factors, cytokines, a GSK3 ⁇ inhibitor, or an AHR antagonist, but is not limited thereto.
- the first medium of a) may include a growth factor, cytokines, and a GSK3 ⁇ inhibitor.
- growth factor means a polypeptide that promotes the division, growth, and differentiation of various cells.
- the growth factor may be, for example, EGF (epidermal growth factor), PDGF-AA (platelet-derived growth factor-AA), IGF-1 (insulin-like growth factor 1), TGF- ⁇ (transforming growth factor- ⁇ ), FGF (fibroblast growth factors), SCF (stem cell factor), and FLT3 (FMS-like tyrosine kinase), and may specifically be any one or more selected from the group consisting of SCF, FLT3, and a combination thereof, but is not limited thereto.
- cytokines are various proteins of relatively small size that are produced in cells and used for cell signaling, and can affect other cells, including themselves. They are generally known to be involved in the immune response to inflammation or infection.
- the cytokines may be, for example, IL (interleukin)-2, IL-3, IL-5, IL-6, IL-7, IL-11, IL-15, IL-21, IL-12, IL-18, BMP4 (bone morphogenetic protein 4), activin A, notch ligand, G-CSF (granulocyte-colony stimulating factor), SDF-1 (stromal cell-derived factor-1), etc., and may specifically be any one or more selected from the group consisting of IL-3, IL-6 IL-15, IL-7, IL-2, IL-21, IL-12, IL-18, and a combination thereof, but are not limited thereto.
- the growth factors and cytokines are included in the medium for directly reprogramming the isolated cells into the target cells, and the types of growth factors and cytokines are not particularly limited as long as they can be used for direct reprogramming.
- GSK3 ⁇ glycogen synthase kinase 3 beta, glycogen synthase kinase-3 ⁇
- inhibitor means a substance that suppresses or inhibits the activity of GSK3 ⁇ .
- the GSK3 ⁇ inhibitor may be, for example, 1-azakenpaullone, 2-D08, 3F8, 5-bromoindole, 6-Bio, A 1070722, aloisine A, AR-A014418, alsterpaullone, AZD-1080, AZD2858, bikinin, BIO, BIO-acetoxime, bisindolylmaleimide I, bisindolylmaleimide I hydrochloride, CAS 556813-39-9, malariapaullone, CHIR98014, CHIR98023, CHIR99021 (CT99021), CP21R7, dibromocantherelline, GSK-3 ⁇ inhibitor I, VI, VII, X, XI, XV, GSK-3 inhibitor IX, XVI, hymenidin, hymenialdisine, HMK-32, I3M (indirubin-3-monoxime, indirubin, indole-3-acetamide, IM-12, kenpau
- the first medium of a) may include SCF, FLT3, IL-3, and IL-6 and CHIR99021, but is not limited thereto.
- the first medium of a) may further include any one or more selected from the group consisting of fetal bovine serum (FBS), antibiotics, and a combination thereof, but is not limited thereto.
- FBS fetal bovine serum
- antibiotics antibiotics, and a combination thereof, but is not limited thereto.
- the antibiotic may be penicillin/streptomycin, but is not limited thereto.
- the first medium of a) may include FBS, penicillin/streptomycin, SCF, FLT3, IL-3, and IL-6 and CHIR99021, but is not limited thereto.
- the first medium of a) may be StemSpan SFEM II containing 8% to 12% FBS, 0.1% to 2% penicillin/streptomycin, 80 ng/mL to 120 ng/mL human SCF, 80 ng/mL to 120 ng/mL human FLT3, 10 ng/mL to 30 ng/mL human IL-3, 10 ng/mL to 30 ng/mL human IL-6, and 2 ⁇ M to 7 ⁇ M CHIR99021, and more specifically StemSpan SFEM II containing 10% FBS, 1% penicillin/streptomycin, 100 ng/mL human SCF, 100 ng/mL human FLT3, 20 ng/mL human IL-3, 20 ng/mL human IL-6, and 5 ⁇ M CHIR99021, but is not limited thereto.
- the second medium of b) may include a growth factor, cytokines, and an AHR (aryl hydrocarbon receptor) antagonist.
- growth factor and “cytokine” are the same as described above.
- AHR aryl hydrocarbon receptor
- TCDD dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin)
- the AHR antagonist may be, for example, StemRegenin I (SRI; 4-(2-((2-benzo[b]thiphen-3-yl)-9-isopropyl-9H-purin-6-yl)amino)ethyl)phenol hydrochloride], CH-223191(1-methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide), etc., and specifically StemRegenin I, but is not limited as long as it plays a role in increasing the efficiency of direct reprogramming.
- the second medium of b) may include SCF, FLT3, IL-15, IL-7, IL-2, and StemRegenin I, but is not limited thereto.
- the second medium of b) may further include any one or more selected from the group consisting of FBS, antibiotics, and a combination thereof, but is not limited thereto.
- the antibiotic may be penicillin/streptomycin, but is not limited thereto.
- the second medium of b) may include FBS, penicillin/streptomycin, SCF, FLT3, IL-15, IL-7, IL-2, and StemRegenin I, but is not limited thereto.
- the second medium of b) may include 8% to 12% FBS, 0.1% to 2% penicillin/streptomycin, 10 ng/mL to 30 ng/mL human SCF, 10 ng/mL to 30 ng/mL human FLT3, 100 IU/mL to 500 IU/mL human IL-2, 10 ng/mL to 30 ng/mL human IL-7, 10 ng/mL to 30 ng/mL human IL-15, and 1 ⁇ M to 3 ⁇ M StemRegenin I, and more specifically 10% FBS, 1% penicillin/streptomycin, 20 ng/mL human SCF, 20 ng/mL human FLT3, 200 IU/mL human IL-2, 20 ng/mL human IL-7, 20 ng/mL human IL-15, and 2 ⁇ M StemRegenin I, but is not limited thereto.
- the third medium of c) may include cytokines, a GSK3 ⁇ inhibitor, and an AHR antagonist.
- cytokines cytokines
- GSK3 ⁇ inhibitor cytokines
- AHR antagonist cytokines
- the third medium of c) may include IL-2, IL-15, IL-21, IL-12, IL-18, CHIR99021, and StemRegenin I, but is not limited thereto.
- the third medium of c) may further include any one or more selected from the group consisting of FBS, antibiotics, and a combination thereof, but is not limited thereto.
- the antibiotic may be penicillin/streptomycin, but is not limited thereto.
- the third medium of c) may include FBS, penicillin/streptomycin, IL-2, IL-15, IL-21, IL-12, IL-18, CHIR99021, and StemRegenin I, but is not limited thereto.
- the third medium of c) may be RPMI 1640 containing 8% to 12% FBS, 0.1% to 2% penicillin/streptomycin, 100 IU/mL to 500 IU/mL human IL-2, 40 ng/mL to 60 ng/mL human IL-12, 10 ng/mL to 30 ng/mL human IL-15, 90 ng/mL to 110 ng/mL human IL-18, 10 ng/mL to 30 ng/mL human IL-21, 1 ⁇ M to 3 ⁇ M CHIR99021, and 1 ⁇ M to 3 ⁇ M StemRegenin I, and more specifically RPMI 1640 containing 10% FBS, 1% penicillin/streptomycin, 200 IU/mL human IL-2, 50 ng/mL human IL-12, 20 ng/mL human IL-15, 100 ng/mL human IL-18, 20 ng/mL human IL-21, 2 ⁇ M CHIR99021, and 2 ⁇
- the isolated cells into which the reprogramming factor and the CAR gene are introduced may be cultured in the first medium of a) for 4 to 7 days, and in the second medium of b) for 10 to 14 days, and then in the third medium of c) for 14 days or more, but is not limited thereto.
- the cells were cultured for different culture periods (3, 5, 7, and 9 days) in the CAR-iNK first medium, and then cultured in the CAR-iNK second medium and the third medium under the same conditions as in Example 1, and the CAR-iNK production yield was analyzed by comparison. As a result, it was confirmed that the highest CAR-iNK production yield of about 80% was obtained when the cells were cultured in the CAR-iNK first medium for 5 days ( FIG. 7A ).
- the CAR-iNK yield efficiency was increased when the cells were cultured in the CAR-iNK third medium containing 20 ng/mL human IL-21, 2 ⁇ M CHIR99021, 2 ⁇ M StemRegenin I (SR1), 50 ng/mL human IL-12, and 100 ng/mL human IL-18 ( FIG. 7B ).
- the CAR-iNK yield efficiency was increased up to 15 times when cultured for 14 days ( FIG. 7B ).
- CAR-iNK cells exhibited the highest production efficiency (CD19-CAR-iNK cells: maximum 45.9% ( FIG. 6A ), MSLN-CAR-iNK cells: 43.7% ( FIG. 4 )), HER2-CAR-iNK cells: 47.8% ( FIG. 5 ) when cultured in the CAR-iNK first medium for 5 days, in the CAR-iNK second medium for 12 days, and in the CAR-iNK third medium for 2 to 3 weeks.
- the CAR-iNK cells produced according to the method of the present invention may express any one or more selected from the group consisting of CD56+, CD16+, CD3 ⁇ , and a combination thereof, but is not limited thereto.
- CD56+”, CD16+, and CD3 ⁇ are indicators on the surface of NK cells, and in the present invention, the expression of CD56+, CD16+, and CD3 ⁇ was analyzed through flow cytometry to determine whether CAR-iNK cells were produced ( FIGS. 3 to 6 ).
- the CAR-iNK cells produced according to the method of the present invention may have an excellent killing ability against various cancer cells.
- the frequency (%) of CD107a+ cells and interferon-gamma+cells having an cancer cell lysis ability was increased in cancer cells co-cultured with the CAR-iNK cells ( FIGS. 8 to 15 ), and as a result of confirming the killing ability of iNK cells against blood cancer cell lines, pancreatic cancer cell lines, prostate cancer cell lines, colorectal cancer cell lines, lung cancer cell lines, liver cancer cell lines, gastric cancer cell lines, and melanoma cell lines, it was confirmed that they exhibited an excellent killing ability ( FIGS. 16 to 18 ).
- Another aspect of the present invention provides CAR-iNK cells produced according to the method above.
- the terms used herein are the same as described above.
- the CAR-iNK cells may have an excellent killing ability against various cancer cells.
- Still another aspect of the present invention provides a cell therapy composition for preventing or treating cancer, including the CAR-iNK cells produced according to the method above, as an active ingredient.
- prevention refers to all actions that suppress or delay cancer by the administration of the composition.
- treatment refers to all actions that alleviate or beneficially change the symptoms of cancer by the administration of the composition.
- cell therapeutic agent refers to a drug for treatment, diagnosis, and prevention (U.S. FDA guidance) containing cells or tissues prepared from humans via isolation, culture, and specialized manipulations, and to a drug for treatment, diagnosis, and prevention prepared by any process including proliferating and selecting autologous, homologous, or heterologous cells ex vivo, or modifying the biological characteristics of cells, so as to restore the function of cells or tissues.
- the cell therapy composition may have an efficacy of preventing or treating cancer by including the CAR-iNK cells produced according to the method of the present invention.
- the cell therapy composition may contain the CAR-iNK cells at 1.0 ⁇ 10 4 cells/mL to 1.0 ⁇ 10 10 cells/mL, preferably 1.0 ⁇ 10 5 cells/mL to 1.0 ⁇ 10 9 cells/mL, based on the total weight of the composition, but is not limited thereto.
- the cell therapy composition may be administered by formulating it into a pharmaceutical formulation in the form of unit dosage suitable for administration to the body of a patient by conventional methods in the pharmaceutical field, and it contains an effective amount by a single dose or in divided doses.
- a formulation for parenteral administration may preferably include injection formulation such as an injection ampoule, infusion formulation such as an infusion bag, and spray formulation such as an aerosol, etc.
- the injection ampoule may be mixed with injection solution such as saline solution, glucose, mannitol, and Ringer's solution just before use.
- the cells can be carried by an infusion bag textured with polyvinyl chloride or polyethylene, and examples thereof may include infusion bags manufactured by Baxter, Becton Dickinson, Medcep, National Hospital Products, or Terumo.
- the pharmaceutical formulation may additionally include one or more pharmaceutically acceptable inactive carriers in addition to the active ingredient, for example, a preservative, analgesic controller, solubilizer, or stabilizer for injection formulation, and a base, excipient, lubricant, or preservative for topical formulation.
- a preservative for example, a preservative, analgesic controller, solubilizer, or stabilizer for injection formulation, and a base, excipient, lubricant, or preservative for topical formulation.
- the thus-produced cell therapy composition of the present invention or a pharmaceutical formulation thereof may be administered in accordance with any conventional method in the art together with other cells used for treatment of cancer, or in the form of a mixture therewith.
- Direct engraftment or transplantation to the diseased area of a patient in need of treatment, or direct transplantation or injection into the abdominal cavity is preferred, but the method is not limited thereto.
- both non-surgical administration using a catheter and surgical administration such as injection or transplantation after incision of the diseased area are possible.
- the composition may also be administered parenterally by the conventional method, for example, transplantation of cells into the hematopoietic system, in addition to direct administration to the lesion.
- the cell therapy composition of the present invention may be administered in an amount ranging from about 0.0001 mg/kg to 1000 mg/kg, preferably 0.001 mg/kg to 100 mg/kg once per day or in several divided doses per day.
- amount of the active ingredient actually administered ought to be determined in light of various relevant factors including the disease to be treated, the severity of the disease, the route of administration, and the body weight, age and sex of a patient, and therefore, the above dose should not be intended to limit the scope of the present invention in any way.
- Yet another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer, including the CAR-iNK cells produced according to the method above, as an active ingredient.
- the cancer may be a cancer showing prevention or treatment results due to an immune response of CAR-iNK cells, etc.
- the cancer may be, for example fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma cancer, osteogenic sarcoma, myeloma, myeloma, myelodysplasia, lymphoma, non-Hodgkin's lymphoma, blood cancer, melanoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelioma, synovial sarcoma, mesothelioma, Ewing's sarcoma, gastric cancer, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, colon cancer, colorectal cancer, rectal cancer, pancreatic cholangiocarcinoma, pancreatic cancer,
- the pharmaceutical composition may have an efficacy of preventing or treating cancer by including the CAR-iNK cells produced according to the method of the present invention.
- the pharmaceutical composition of the present invention may contain the CAR-iNK cells at 1.0 ⁇ 10 4 cells/mL to 1.0 ⁇ 10 10 cells/mL, preferably 1.0 ⁇ 10 5 cells/mL to 1.0 ⁇ 10 9 cells/mL, based on the total weight of the composition, but is not limited thereto.
- the pharmaceutical composition may further include a pharmaceutically acceptable carrier, excipient or diluent commonly used in the preparation of the pharmaceutical compositions, and the carrier may include a carrier which does not occur naturally.
- the carriers, excipients, and diluents may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and minerals.
- the pharmaceutical composition may be formulated according to a conventional method into a tablet, a pill, a powder, a granule, a capsule, a suspension, a solution for internal use, an emulsion, a syrup, a sterilized aqueous solution, a non-aqueous solution, a suspension, an emulsion, a lyophilized preparation, a transdermal preparation, a gel, a lotion, an ointment, a cream, a patch, a cataplasma form, a paste, a spray, a skin emulsion, a skin suspension, a transdermal patch, a drug-containing bandage, or a suppository for use.
- the preparation may be formulated with commonly used diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc.
- Solid formulations for oral administration may include tablets, pills, powders, granules, capsules, etc., but are not limited thereto.
- Such solid formulations may be prepared by mixing with at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc.
- lubricants such as magnesium stearate or talc may also be used.
- Liquid formulations for oral administration may be prepared by adding various excipients, for example, wetting agents, flavoring agents, aromatics, preservatives, etc. in addition to liquid paraffin.
- Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories.
- the non-aqueous solutions and the suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyloleate, etc.
- the base for suppositories may include witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin, etc.
- the pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount.
- pharmaceutically effective amount means an amount which is sufficient to treat diseases at a reasonable benefit/risk ratio applicable to any medical treatment.
- the effective dosage level may be determined depending on factors including a kind of a subject and severity, age, sex, activity of a drug, drug sensitivity, administration time, administration route, excretion rate, duration of treatment, drugs used concurrently, and other factors known in the medical field.
- the pharmaceutical composition may be administered in a daily dosage of 0.0001 mg/kg to 1000 mg/kg, and specifically 0.001 mg/kg to 100 mg/kg, and the dose may be administered once per day or in several divided doses per day.
- the pharmaceutical composition may be administered alone as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with existing therapeutic agents.
- the composition may be administered in a single or multiple dosage form. It is important to administer the composition in a minimum amount that may exhibit a maximum effect without causing side effects, considering all of the above-described factors. The amount may be readily determined by those skilled in the art.
- the term “administration” means introducing the composition of the present invention into a subject by any suitable method.
- the administration route of the composition may be administered through any general route as long as it can reach the target tissue, including intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, and intranasal administration, but is not limited thereto.
- the term “subject” refers to any animal, including humans, monkeys, cattle, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits or guinea pigs having cancer or at risk of having cancer. As long as the disease can be effectively prevented or treated by administering the pharmaceutical composition of the present invention into a subject, any type of subject may be included without limitation.
- Even another aspect of the present invention provides a method for treating cancer, including administering the cell therapy composition or the pharmaceutical composition to a subject except a human.
- the present invention provides a simplified production process because CAR-iNK cells are produced from isolated cells through direct reprogramming and a production time of at least 32 days, which is shorter than that obtained by the method in which the CAR gene was introduced after producing NK cells using conventional reprogramming techniques, thereby reducing costs, has excellent NK cell production efficiency of 47.8% at maximum, and ensures safety as the cells are produced without passing through pluripotent stem cells, thereby showing an excellent CAR-iNK cell production effect that is distinguished from that of the conventional reprogramming techniques.
- the present invention is distinguished from the conventional method of obtaining NK cells through direct harvesting, stem cell differentiation, etc. in that NK cells can be directly produced by culturing cells, which have a different cell lineage from NK cells and are easy to collect, in a reprogramming medium, and thus, the present invention is meaningful in that it can provide a wide range of options for cell types and quality.
- the CAR-iNK cells produced according to the method of the present invention have an excellent cancer cell killing ability as described above, and thus can be provided as a cell therapy composition and a pharmaceutical composition for preventing or treating cancer including the same.
- CAR chimeric antigen receptor
- HER2 human epidermal growth factor receptor 2
- MSLN mouse epidermal growth factor receptor 2
- scFv antibody domain
- CD19-CAR1 gene including CD8 leader (SEQ ID NO: 1), CD19 scFv (SEQ ID NO: 2), CD8 hinge (SEQ ID NO: 5), CD8 transmembrane (TM) domain (SEQ ID NO: 6), Fc- ⁇ (gamma) receptor (SEQ ID NO: 7), and GFP (green fluorescent protein) (SEQ ID NO: 11);
- CD19-CAR2 gene including CD8 leader (SEQ ID NO: 1), CD19 scFv (SEQ ID NO: 2), CD8 hinge (SEQ ID NO: 5), CD8 transmembrane domain (SEQ ID NO: 6), CD28 intracellular domain (SEQ ID NO: 8), CD3 (zeta) (SEQ ID NO: 9), IRES (internal ribosome entry site) (SEQ ID NO: 10), and GFP (SEQ ID NO: 11);
- MSLN-CAR gene including CD8 leader (SEQ ID NO: 1), MSLN (mesothelin) scFv (SEQ ID NO: 3), CD8 hinge (SEQ ID NO: 5), CD8 transmembrane domain (SEQ ID NO: 6), CD28 intracellular domain (SEQ ID NO: 8), CD3 (SEQ ID NO: 9), IRES (SEQ ID NO: 10), and GFP (SEQ ID NO: 11); and
- HER2-CAR gene including CD8 leader (SEQ ID NO: 1), HER2 (human epidermal growth factor receptor 2) scFv (SEQ ID NO: 4), CD8 hinge (SEQ ID NO: 5), CD8 transmembrane domain (SEQ ID NO: 6), CD28 intracellular domain (SEQ ID NO: 8), CD3 (SEQ ID NO: 9), IRES (SEQ ID NO: 10), and GFP (SEQ ID NO: 11).
- the IRES was inserted for cloning the CAR gene into a vector constituting a double cistron.
- each domain of FIG. 1 was synthesized from CAR1 (Addgene ID: 113014), and CAR-expressing lentiviruses were constructed through overlap PCR (Gibson assembly).
- PBMC peripheral blood mononuclear cells
- stempro SFEM II containing 2.5% Stem Pro-34 nutrient supplement, 2 mM Glutamax I, 1% penicillin/streptomycin, 20 ng/mL human IL (interleukin)-3, 20 ng/mL human IL-6, 100 ng/mL human stem cell factor (SCF), and 100 ng/mL human FLT3 (FMS-like tyrosine kinase)
- SCF human stem cell factor
- FLT3 FMS-like tyrosine kinase
- the Sendai virus system [Oct4, Sox2, Klf4, and Myc-expressing RNA-based Sendai virus (CytoTune 2.0 Sendai Reprogramming Kit, Thermo Scientific); OSKM-SeV] expressing the reprogramming factors and the 4 types of lentiviruses expressing the 4 types of CARs of Example 1 were used.
- the cells were cultured in a standard culture medium (SCM medium) containing the Sendai virus (5 MOI), PBMC and polybrene (4 ⁇ g/mL) for 1 day, and then sequentially cultured in the first medium, second medium, and third medium shown below.
- SCM medium standard culture medium
- Sendai virus 5 MOI
- PBMC peripheral blood mononuclear cells
- polybrene 4 ⁇ g/mL
- the cells transformed by the method (2 ⁇ 10 5 cells/48-well plate) were cultured in the first CAR-iNK medium (StemSpan SFEM II containing 10% FBS, 1% penicillin/streptomycin, 100 ng/mL human SCF, 100 ng/mL human FLT3, 20 ng/mL human IL-3, 20 ng/mL human IL-6, and 5 ⁇ M CHIR99021) including the GSK3 ⁇ (glycogen synthase kinase 3 ⁇ ) inhibitor for 5 to 6 days, and then cultured in the CAR-iNK second medium (StemSpan SFEM II containing 10% FBS, 1% penicillin/streptomycin, 20 ng/mL human SCF, 20 ng/mL human FLT3, 200 IU/mL human IL-2, 20 ng/mL human IL-7, 20 ng/mL human IL-15, and 2 ⁇ M StemRegenin I) including the AHR (aryl hydrocarbon receptor) antagonist for 12 days
- the CAR-expressing lentiviruses were inoculated into a culture medium selected from the step of culturing in the CAR-iNK first medium (day 4), the CAR-iNK second medium (day 14), or the CAR-iNK third medium (day 24) simultaneously with the reprogramming factor (day 0) or after introduction of the reprogramming factor, as shown in FIG. 2 , and thus were transformed into the cells during the reprograming process by which PBMC were converted into NK cells.
- NK cells introduced with the CD19-CAR1 gene, CD19-CAR2 gene, MSLN-CAR gene, or HER2-CAR gene were prepared through the direct reprogramming, the cells were stained with the CD56 antibody, CD3 antibody, CD19 antigen, MSLN antigen, and HER2 antigen, and then iNK cell group (CD56+ and CD3 ⁇ ), CD19 CAR-iNK cell group (CD56+ and CD19+), MSLN CAR-iNK cell group (CD56+and MSLN+), and HER2 CAR-iNK cell group (CD56+and HER2+) were analyzed using flow cytometry.
- NK (iNK) cells induced through direct reprogramming were added to a phosphate buffer (FACS buffer) containing 1% BSA (bovine serum albumin) and 2 mM EDTA (ethylenediaminetetraacetic acid), supplemented with fluorescent-labeled antibodies and antigens, and reacted at room temperature for 20 minutes, and subsequently, the cells were washed and recovered using a centrifuge, and then analyzed by FACS (BD Bioscience).
- FACS buffer phosphate buffer
- BSA bovine serum albumin
- EDTA ethylenediaminetetraacetic acid
- each CAR gene was inserted into the genome of iNK cells
- genomic DNA of each cell was analyzed with primers (SEQ ID NOS: 12 and 13) for CD19 CAR, primers (SEQ ID NOS: 14 and 15) for MSLN CAR, and primers (SEQ ID NOS: 16 and 17) for HER2 CAR through PCR gene analysis.
- CD56+CD3 ⁇ CD19-CAR-iNK cells were produced with a maximum efficiency of 45.9% ( FIG. 3 and FIG. 6A ), that CD56+CD3 ⁇ MSLN-CAR-iNK were produced with a maximum efficiency of 43.7% ( FIG. 4 ), and that CD56+CD3 ⁇ HER2-CAR-iNK cells were produced with a maximum efficiency of 47.8% ( FIG. 5 ).
- the cells were cultured in the CAR-iNK first medium for different incubation periods (3, 5, 7, and 9 days), and then cultured in the CAR-iNK second medium and the third medium under the same conditions as in Example 1, and the CAR-iNK production yield was analyzed by comparison.
- the CAR-iNK yield efficiency was increased when cultured in the CAR-iNK third medium containing 20 ng/mL human IL-21, 2 ⁇ M CHIR99021, 2 ⁇ M StemRegenin 1 (SR1), 50 ng/mL human IL-12, and 100 ng/mL human IL-18 ( FIG. 7B ).
- the CAR-iNK yield efficiency was increased up to 15 times when cultured for 14 days ( FIG. 7B ).
- the CAR-iNK cells were cultured in the CAR-iNK first medium for 5 days, in the CAR-iNK second medium for 12 days, and in the CAR-iNK third medium for 2 to 3 weeks.
- the frequency of CD107a+ cells was confirmed through flow cytometry. Specifically, the frequency of CD107a+ cells was determined through FACS analysis after reacting the CAR-iNK cells in FACS buffer supplemented with fluorescent-labeled antibodies against CD56 and CD107a at room temperature for 20 minutes, and then washing and recovering the cells using a centrifuge.
- the frequency of IFN-gamma cells was confirmed through flow cytometry. Specifically, the frequency of IFN-gamma cells was determined after reacting the CAR-iNK cells in a phosphate buffer containing 0.5% Tween 20 and 0.5% BSA at room temperature for 20 minutes, and then washing and recovering the cells using a centrifuge. The recovered cells were reacted at room temperature for 20 minutes in FACS buffer supplemented with fluorescent-labeled antibodies against CD56 and IFN-gamma, and then the cells were washed and recovered using a centrifuge and subjected to FACS analysis.
- the cell killing ability of the CAR-iNK cells produced in Example 1 was measured using calcein-AM.
- the iNK cells were prepared by diluting the cells to a density of 0.25 ⁇ 10 5 cells/mL and 1 ⁇ 10 5 cells/mL using a culture solution, and then dispended in a 96-well plate in an amount of 100 mL.
- the thus-prepared calcein-labeled target cancer cells (1 ⁇ 10 5 cells/mL) were added to a 96-well plate in an amount of 100 pUwell, centrifuged at 400 g for 1 minute, and then cultured in a cell incubator at 37° C. for 4 hours in the presence of 5% CO 2 , and subsequently, 100 ⁇ L of the supernatant was taken from each well and measured with a fluorescence plater reader (485 nm/535 nm).
- the cell killing ability (%) was calculated according to the following formula.
- Cancer Cell Killing Ability(%) ⁇ (Measured Value ⁇ Minimum Value)/(Measured Value ⁇ Minimum Value) ⁇ 100
- the minimum value is the measured value of a well in which only calcein-labeled target cancer cells exist
- the maximum value is the measured value of a well in which cells are completely lysed by adding 0.1% TritonX-100 to the calcein-labeled target cancer cells.
- CD19-CAR-iNK cells FIG. 16
- MSLN-CAR-iNK cells FIG. 17
- HER2-CAR-iNK cells FIG. 18
- the tumor size formed in the iNK (5.35 ⁇ 10 9 radiance) and CAR-NK (3.83 ⁇ 10 9 radiance) cell experimental groups was significantly reduced compared to the tumor size (1.21 ⁇ 10 10 radiance) of the control group formed under the condition of PBS injection on the 14th day, thereby confirming that the CAR-iNK cells exhibited an excellent anticancer effect compared to iNK cells ( FIG. 19 ).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
- The present invention relates to a method for producing induced natural killer (iNK) cells into which a chimeric antigen receptor (CAR) gene encoding a CAR is introduced, iNK cells produced by the method, and a cell therapy composition and a pharmaceutical composition for preventing or treating cancer, including the iNK cells.
- NK (natural killer) cells are key innate immune cells that perform the body's primary defense (innate immunity) function by immediately recognizing and eliminating infections of viruses, bacteria and parasites, and abnormal autologous cells (especially cancer cells). Unlike T cells, which recognize target cells by expressing antigen-specific receptors, NK cells perceive abnormal changes in target cells (especially cancer cells), such as balance of inhibitory or activating receptors, i.e., killer immunoglobulin receptors (KIR), natural cytotoxicity receptors (NCR), DNAM-1 (DNAX accessory molecule-1), and NKG2D (
NK group 2 member D, and loss of surface MHC (major histocompatibility complex) class I antigen, without antigen specificity and human leukocyte antigen (HLA) matching, and have contact-dependent cytotoxicity. - Specifically, NK cells can kill cancer cells by directly mediating target cancer cell apoptosis through secretion of cytokines, such as perforin (Prf1), granzyme B (GzmB), interferon-γ (IFN-γ), interleukin (tumor necrosis factor-α; TNF-α), etc., and activation of apoptosis-inducing receptors (Fas, tumor necrosis factor-related apoptosis-inducing ligand; TRAIL). In addition, it is known that NK cells that express Fc receptor-FcRγIIIa (CD16) can effectively eliminate cancer cells directly or indirectly by inducing acquired immunity as well as innate immunity, such as mediating antibody-dependent cellular cytotoxicity (ADCC). In particular, unlike T cells, NK cells do not cause side effects such as graft-versus-host disease (GVHD), and thus have gained attention as a safe cell source that can be used for the development of not only autologous but also allogeneic anticancer immune cell therapeutics.
- Currently, human NK cells are produced by isolating and proliferating a small amount of cells present in the human body [peripheral blood, bone marrow, umbilical cord blood, etc.] through a primary culture method, or can be obtained multidimensionally from stem cells having the ability to differentiate into NK cells [hematopoietic stem cells (HSCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs)] through differentiation induction culture.
- Recently, it has been demonstrated that T cells (CAR-T cells), which are produced by introducing a cancer cell target chimeric antigen receptor (CAR) gene as a method for promoting specificity and activation for target cancer cells and consequently enhancing the efficacy of anticancer treatment, have an enhanced anticancer effect in the treatment of blood cancer, and thus have received much interest in the development of CAR-immune cell therapeutics. However, cytokine release syndrome (CRS) induced by interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-1, and IL-6 factors secreted by CAR-T cells is recognized as a serious problem that needs to be solved. Further, CAR-T cells are known to inhibit cancer cell cytotoxicity by the immune checkpoint protein PD (programmed death ligand)-1, etc. in the tumor microenvironment (TME) of solid tumors, and accordingly, there is a need for technology development to improve the efficacy of solid cancer treatments.
- However, since NK cells secrete IL-3 and granulocyte-macrophage colony-stimulating factor, they are less likely to cause CRS [K. Rezvani, R. Rouce, E. Liu et al., Engineering Natural Killer Cells for Cancer Immunotherapy, Mol. Ther., 25 (2017), pp. 1769-1781]. Additionally, the level of PD-1 secreted by NK cells is substantially low, and almost no immunosuppression is induced, and also, it is known that NK cells enable migration of dendritic cells to tumors, thereby enhancing anti-PD-1 immunotherapy [K. C. Barry, J. Hsu, M. L. Broz, et al. A Natural Killer-dendritic Cell Axis Defines Checkpoint Therapy-responsive Tumor Microenvironments, Nat. Med., 24 (2018), pp. 1178-1191], and thus, the excellence of CAR-NK development has been demonstrated. Further, it was confirmed from the results of preclinical and clinical trials for CAR-NK cell therapy that NK cells can effectively remove blood cancer and solid cancer cells [E. L. Siegler, Y. Zhu, P. Wang, et al. Off-the-shelf CAR-NK Cells for Cancer Immunotherapy, Cell Stem Cell, 23 (2018), pp. 160-161], and thus have been recognized to have the potential to be developed as anticancer immune cell therapeutics in a wide range, including for solid cancers.
- As a method for producing CAR-NK cells, a method for introducing a CAR gene specific for a cancer antigen into a single NK cell line (NK-92, iPSC, etc.) that is relatively easy to culture and proliferate, and isolating and amplifying CRA-expressing NK cells is mainly used. The most used primary cultured NK-92 cells are cells derived from patients with malignant non-Hodgkin's lymphoma and have the potential to induce secondary tumorigenesis and EB (Epstein-Barr) virus sensitivity after injection. Thus, in order to ensure safety, a lethal irradiation process is essential before clinical application, but this process shortens the in vivo survival time of CAR-NK-92 cells, and consequently, the anticancer effect is reduced. The method of producing NK cells by introducing a CAR gene into induced pluripotent stem cells (iPSCs) and inducing differentiation essentially requires not only the CAR-iPSCs process, and isolation and amplification process, but also a complex differentiation process that involves much time and cost, and carries the possibility of tumor formation, and thus, it is essential to develop a technology that can secure and maintain safety.
- Recently, a technology for directly producing high-value-added functional human tissue-specific target cells having characteristics of a different lineage from initial human somatic cells, which are relatively easy to obtain using reprogramming technology of somatic cells, is rapidly developing. However, there has been no report on a technology for directly producing CAR-NK cells without passing through iPSCs by somatic cell reprogramming.
- The present inventors have made extensive efforts to develop a method for efficiently producing CAR-NK cells, and as a result, they have developed a CAR-NK cell-specific reprogramming medium and reprogramming culture conditions, and confirmed that CAR-NK cells can be produced from human somatic cells by a method that does not require a differentiation process without limiting the initial cell resources, and accordingly, the produced CAR-NK cells exhibit an excellent cancer cell killing ability and thus can be applied to the prevention or treatment of cancer, thereby completing the present invention.
- It is one object of the present invention to provide a method for producing CAR-iNK (induced natural killer) cells, including: culturing isolated cells, into which a reprogramming factor and a CAR (chimeric antigen receptor) gene are introduced, sequentially in a) a first medium containing growth factors, cytokines, and a GSK3β (
glycogen synthase kinase 3 beta) inhibitor; b) a second medium containing growth factors, cytokines, and an AHR (aryl hydrocarbon receptor) antagonist; and c) a third medium containing cytokines, a GSK3β inhibitor, and an AHR antagonist, and thereby directly reprogramming into NK cells. - It is another object of the present invention to provide CAR-iNK cells produced according to the method.
- It is still another object of the present invention to provide a cell therapy composition for preventing or treating cancer, including the CAR-iNK cells produced according to the method above, as an active ingredient.
- It is yet another object of the present invention to provide a pharmaceutical composition for preventing or treating cancer, including the CAR-iNK cells produced according to the method above, as an active ingredient.
- The method according to the present invention can produce iNK cells, into which a CAR gene is introduced, from the isolated cells without a differentiation process through direct reprogramming, thereby producing CAR-NK cells with an enhanced cancer cell killing function with high efficiency without limitation of the initial cells, and has an effect of reducing cost and time by simplifying the production process. Since NK cells can be produced without passing through induced pluripotent stem cells produced through a conventional reprogramming technique, there is an excellent NK cell production effect which is enhanced and distinguished in terms of safety. In addition, the CAR gene-introduced iNK cells produced by the above method have an excellent cancer cell killing ability, and thus can be effectively utilized as a cell therapy composition or a pharmaceutical composition for preventing or treating cancer.
-
FIG. 1 shows a diagram showing the constitutional domains of four CAR genes. -
FIG. 2 is a schematic diagram showing a method for producing CAR-iNK by direct somatic cell reprogramming and CAR gene introduction. -
FIG. 3 is a result confirming CD19-CAR-iNK cells produced from PBMC. -
FIG. 4 is a result confirming MSLN-CAR-iNK cells produced from PBMC. -
FIG. 5 is a result confirming HER2-CAR-iNK cells produced from PBMC. -
FIG. 6 (A) shows a result confirming the CD19-CAR-iNK cells produced according to the introduction period of CAR-expressing lentivirus (day 0,day 14, day 24), and (B) shows a result confirming the insertion of the CD19-CAR gene in the iNK cells produced from PBMC. -
FIG. 7 is a result confirming the CAR-iNK production efficiency according to the composition or incubation time of the CAR-iNK first medium and third medium. -
FIG. 8 is a result confirming the frequency of CD107a-expressing cells during co-culture of the produced CD19-CAR-iNK cells and cancer cells. -
FIG. 9 is a result confirming the frequency of CD107a-expressing cells during co-culture of the produced CD19-CAR-iNK cells and cancer cells. -
FIG. 10 is a result confirming the frequency of CD107a-expressing cells during co-culture of the produced MSLN-CAR-iNK cells and cancer cells. -
FIG. 11 is a result confirming the frequency of CD107a-expressing cells during co-culture of the produced HER2-CAR-iNK cells and cancer cells. -
FIG. 12 is a result confirming the frequency of IFN-gamma-expressing cells during co-culture of the produced CD19-CAR-iNK cells and cancer cells. -
FIG. 13 is a result confirming the frequency of IFN-gamma-expressing cells during co-culture of the produced CD19-CAR-iNK cells and cancer cells. -
FIG. 14 is a result confirming the frequency of IFN-gamma-expressing cells during co-culture of the produced MSLN-CAR-iNK cells and cancer cells. -
FIG. 15 is a result confirming the frequency of IFN-gamma-expressing cells during co-culture of the produced HER2-CAR-iNK cells and cancer cells. -
FIG. 16 is a result confirming the cancer cell killing ability of the produced CD19-CAR-iNK cells. -
FIG. 17 is a result confirming the cancer cell killing ability of the produced MSLN-CAR-iNK cells. -
FIG. 18 is a result confirming the cancer cell killing ability of the produced HER2-CAR-iNK cells. -
FIG. 19 is a result confirming the tumor growth inhibitory effect of MSLN-CAR-iNK cells in a pancreatic cancer cell xenograft mouse animal model. - The present invention will be described in detail below. Meanwhile, each description and embodiment disclosed herein can be applied to other descriptions and embodiments, respectively. That is, all combinations of various elements disclosed herein fall within the scope of the present invention. Further, the scope of the present invention is not limited by the specific description described below.
- In order to achieve the above objects, one aspect of the present invention provides a method for producing CAR-iNK (induced natural killer) cells, including: culturing isolated cells, into which a reprogramming factor and a CAR (chimeric antigen receptor) gene are introduced, sequentially in a) a first medium containing growth factors, cytokines, and a GSK3β (
glycogen synthase kinase 3 beta) inhibitor; b) a second medium containing growth factors, cytokines, and an AHR (aryl hydrocarbon receptor) antagonist; and c) a third medium containing cytokines, a GSK3β inhibitor, and an AHR antagonist, and thereby directly reprogramming into NK cells. - As used herein, the “NK (natural killer) cell” is a key innate immune cell that performs the body's first defense (innate immunity) function to eliminate infections of viruses, bacteria and parasites, and abnormal autologous cells (cancer cells, etc.). NK cells have been proven to be effective in preventing the occurrence, proliferation, metastasis, and recurrence of various types of cancers including not only blood cancer but solid cancers, and thus have received attention as a useful cellular resource for anticancer therapeutics and relapse inhibitors. Efforts to develop NK cells isolated and cultured from the human body and NK cells differentiated from stem cells as anticancer immune cell therapeutics are rapidly increasing, but low NK production efficiency and anticancer treatment efficacy are still recognized as problems to be overcome.
- As a method to promote the specificity and activation for cancer cells, NK (CAR-NK) cells expressing a chimeric antigen receptor (CAR) specific to various cancer antigens were produced, and accordingly, studies are being actively conducted to investigate the enhancement of cancer cell killing ability and its therapeutic efficacy. As a method for producing the CAR-NK cells, a method of introducing cells into a single NK cell line (NK-92, iPSCs, etc.) that is relatively easy to culture and proliferate is mainly used, but low production efficiency, a complicated process, and safety issues (possibility of tumor formation, etc.) have been recognized as problems to be overcome.
- Therefore, the present inventors have attempted to produce CAR-NK cells using a method that is applicable to various human somatic cells that are easy to collect under ex vivo culture conditions and does not require a differentiation process, and a result, they have identified for the first time a method for directly inducing and producing CAR-NK cells from isolated human somatic cells through direct reprogramming.
- As used herein, the term “CAR-iNK (CAR-induced natural killer) cell” refers to an NK (natural killer) cell which is induced through direct reprogramming according to the method of the present invention and into which a CAR gene is introduced.
- As used herein, the term “reprogramming” refers to a method of converting a lineage into a target cell having completely different characteristics by controlling the global gene expression pattern of a specific cell. Reprogramming may include dedifferentiation of cells, direct reprogramming or direct conversion, or direct trans-differentiation, but is not limited thereto. In the present invention, the reprogramming may be performed by introducing a vector containing a foreign gene or DNA into a cell. As used herein, the term “transformation” refers to the change of a cell to a different state, and the term “differentiation” refers to a phenomenon in which daughter cells produced by cell division acquire a function different from that of the original parent cell, and as used herein, the “conversion” and “differentiation” can be used interchangeably with “induction”.
- As used herein, the term “direct reprogramming” refers to a method of inducing direct conversion to a target cell by culturing a specific cell in a reprogramming medium. In order to produce NK cells, which are target cells, using conventional reprogramming techniques, 1) induced pluripotent stem cells were produced from isolated somatic cells; 2) hematopoietic stem (progenitor) cells, the intermediate, were subjected to primary differentiation and production from induced pluripotent stem cells; 3) and subsequently, NK cells, which are target cells, were subjected to secondary differentiation and production from differentiated stem (progenitor) cells. As described above, the conventional technique has the disadvantages of low production efficiency and high time and cost consumption, because it has to sequentially go through a complex culture process. In addition, since NK cells are produced via induced pluripotent stem cells with pluripotency, the remaining undifferentiated cells have the potential to form tumors, and thus safety is an important issue to be verified. In contrast, the present invention produces NK cells, which are the target cells, directly from isolated somatic cells through direct reprogramming, thereby providing reduced production time and cost, and excellent efficiency and safety, and thus can be distinguished from the prior art and can provide an alternative that can overcome the problems. The direct reprogramming may be used interchangeably with direct dedifferentiation, direct differentiation, direct conversion, direct cross-differentiation, cross-differentiation, etc., and as used herein, the direct reprogramming may mean direct dedifferentiation or cross-differentiation into NK cells from isolated somatic cells, but is not limited thereto.
- As used herein, the term “differentiated cells” refers to a state in which cells with specialized structures or functions, that is, cells, tissues, etc. of living organisms, have changed into a form and function suitable for performing the role assigned thereto. For example, the differentiated cells broadly refer to ectodermal, mesodermal, and endodermal cells derived from pluripotent stem cells such as embryonic stem cells, and narrowly to red blood cells, white blood cells, platelets, etc. derived from hematopoietic stem cells.
- As used herein, the “lineage-conversion cell” is a cell which is converted to a cell type with different lineage characteristics due to the change in the intrinsic lineage characteristics of the cell embryologically or artificially (e.g., reprogramming, etc.), thereby having the characteristics of a cell type that are completely different from the characteristics of the cell type before conversion. In the present invention, the lineage-conversion cell may be a target cell. For example, non-NK lymphocyte cells in peripheral blood mononuclear cells may be converted to NK cells in a reprogramming medium, but are not limited thereto.
- In the present invention, the method may be performed by culturing isolated cells, into which a reprogramming factor and a CAR gene are introduced, sequentially in a) a first medium containing growth factors, cytokines, and a GSK3β (
glycogen synthase kinase 3 beta) inhibitor; b) a second medium containing growth factors, cytokines, and an AHR (aryl hydrocarbon receptor) antagonist; and c) a third medium containing cytokines, a GSK3β inhibitor, and an AHR antagonist, and thereby directly reprogramming into NK cells. - As used herein, the term “isolated cells” are not particularly limited, but specifically refer to cells whose lineage has already been specified, such as germ cells, somatic cells, or progenitor cells. The “somatic cells” refer to all cells in which differentiation constituting animals and plants has been completed except for germ cells. The “progenitor cells” refer to a mother cell which does not express a differentiated character, but has a differentiation fate, if it has been found that a cell corresponding to its progeny expresses a certain differentiation character. For example, as for the nerve cells (neurons), nerve fibroblasts (neuronal stem cells) correspond to the precursor cells, and as for the myotube, myoblasts correspond to the precursor cell.
- The isolated cells may be cells derived from a human, but are not limited thereto, and cells derived from various individuals may also fall within the scope of the present invention. In addition, the isolated cells of the present invention may include both in vivo or ex vivo cells. Specifically, the isolated cells may be somatic cells, and more specifically, somatic cells other than NK cells, but are not limited thereto.
- As used herein, the term “reprogramming factor” refers to a gene (or polynucleotide) that can be introduced into a cell to induce reprogramming, or a protein encoded therefrom. The reprogramming factor may vary depending on the target cell to be obtained through reprogramming, and the type of cell before reprogramming. For example, when isolated somatic cells are to be induced into NK cells, the reprogramming factor introduced into the isolated somatic cells may include any one or more selected from the group consisting of Lin28, Asc11, Pitx3, Nurr1, Lmx1a, Nanog, Oct4, Oct3, Sox2, Klf4, Myc, and a combination thereof, and specifically Oct4, Sox2, Klf4, and Myc, but is not limited thereto, and may include any factor known in the art as long as it is a reprogramming factor that can induce the isolated somatic cells into NK cells. The reprogramming using the reprogramming factor is the induction of conversion to a target cell by controlling the entire gene expression pattern of the cell, and the cell may be reprogrammed into a target cell having a gene expression pattern of a desired type of cell by introducing the reprogramming factor into the cell and culturing the same for a certain period of time.
- As used herein, the “introduction of reprogramming factor” may be a method of administering a reprogramming factor to a culture solution of cells; a method of directly injecting a reprogramming factors into cells; a method of increasing the expression level of a reprogramming factor present in a cell; a method of transforming a cell with an expression vector containing a gene encoding a reprogramming factor; a method of modifying a gene sequence to increase the expression of a gene encoding a reprogramming factor; a method of introducing an exogenously expressed gene encoding a reprogramming factor; a method of treating a substance having an effect of inducing expression of the reprogramming factor; and a method of increasing the expression level of a reprogramming factor in a cell through a combination thereof, but is not limited thereto as long as it can increase the expression level of the reprogramming factor. In particular, the introduction of reprogramming factor may be inducing expression of a reprogramming factor depending on a desired time and conditions. Specifically, the method of introducing a reprogramming factor into a cell may be a method of administering a reprogramming factor to a cell culture solution, or a method of transforming a cell with an expression vector containing a gene encoding a reprogramming factor, but this not limited.
- The method of directly injecting a reprogramming factor into a cell may be performed by selecting any method known in the art, but is not limited thereto, and may be performed by appropriately selecting from the methods using microinjection, electroporation, particle bombardment, direct muscle injection, an insulator, and a transposon.
- As used herein, the term “vector” refers to a DNA construct containing the nucleotide sequence of a suitable regulatory sequence and the target protein or polypeptide so as to be able to express the target protein or polypeptide in a suitable host cell. The regulatory sequence may include a promoter, an operator, an initiation codon, a termination codon, a polyadenylation signal, an enhancer, etc. The vector of the present invention may include a signal sequence or a leader sequence for membrane targeting or secretion, in addition to the regulatory sequence, and can be prepared in various ways depending on the desired purpose. The promoter of the vector may be constitutive or inducible. Further, the vector may include a selective marker for selecting a host cell containing the vector, and in the case of a replicable vector, may include a replication origin. Once transformed into a suitable host cell, the vector may replicate or function independently of the host genome, or may integrate into the genome thereof.
- The vector used in the present invention is not particularly limited as long as it is able to replicate in the host cell, and any vector known in the art may be used. Examples of the vector conventionally used may include natural or recombinant virus vector, episomal vector, plasmid vector, cosmid vector, etc.
- Specifically, the virus vector may include vectors derived from retrovirus such as Sendai virus, lentivirus, HIV (human immunodeficiency virus, MLV (murine leukemia virus), ASLV (avian sarcoma/leukosis), SNV (spleen necrosis virus), RSV (Rous sarcoma virus), MMTV (mouse mammary tumor virus), etc., adenovirus, adeno-associated virus, herpes simplex virus, and more specifically, it may be an RNA-based virus vector, but is not limited thereto.
- The episomal vector is a non-viral non-insertable vector, and is known to have a property of expressing a gene included in the vector without being inserted into a chromosome. Accordingly, the cell containing the episomal vector may include both cases in which the episomal vector is inserted into the genome or is present in a cell without being inserted into the genome.
- As used above, the term “operably linked” refers to a functional linkage between a nucleic acid expression regulatory sequence and a nucleic acid sequence encoding a target protein so as to perform a general function. The operative linkage with the recombinant vector can be prepared using genetic recombination techniques well known in the art, and site-specific DNA cleavage and ligation are carried out using enzymes generally known in the art.
- As used herein, the term “CAR gene” refers to a gene encoding a chimeric antigen receptor consisting of an extracellular domain, a transmembrane domain, and an intracellular domain including genes encoding the extracellular domain, the transmembrane domain, and the intracellular domain including an antibody domain (scFv). For the purpose of the present invention, the CAR gene may be any one or more selected from the group consisting of a CD19-CAR1 gene or CD19-CAR2 gene including CD19 scFv, a MSLN-CAR gene including MSLN (mesothelin) scFv, and a HER2-CAR gene including HER2 (human epidermal growth factor receptor 2) scFv, but is not limited thereto.
- It is known that the CAR target factors for solid tumors include EGFRvIII (Morgan R A, Hum Gene Ther. 2012; 23:1043-1053), MUC-1 (Wilkie S, J Immunol. 2008; 180:4901-4909), MAGE (Willemsen R A, Gene Ther. 2001; 8:1601-1608), CEA (Emtage P C, Clin Cancer Res. 2008; 14:8112-8122), PSMA, GD2, CA125, Her2 and MSLN, FAP, VEGFR (Kakarla S, Cancer J. 2014; 20:151-155), etc.
- Additionally, the CD19 is the cluster of differentiation (CD) assigned with number 19 for identifying cell surface molecules according to the immunophenotype, and the CD19 refers to a marker of B lymphocytes. The CD19 is known to be expressed in most B-cell malignant cancer cells and thus provides an ideal target for these carcinomas.
- Specifically, the CAR gene may be any one or more selected from the group consisting of:
- i) a CAR gene (CD19-CAR1 gene) including CD8 leader, CD19 scFv, CD8 hinge, CD8 transmembrane domain, and Fc-γ receptor;
- ii) a CAR gene (CD19-CAR2 gene) including CD8 leader, CD19 scFv, CD8 hinge, CD8 transmembrane domain, CD28 intracellular domain, CD3ζ, and IRES (internal ribosome entry site);
- iii) a CAR gene (MSLN-CAR gene) including CD8 leader, MSLN (mesothelin) scFv, CD8 hinge, CD8 transmembrane domain, CD28 intracellular domain, CD3ζ, and IRE; and
- iv) a CAR gene (HER2-CAR gene) including CD8 leader, HER2 (human epidermal growth factor receptor 2) scFv, CD8 hinge, CD8 transmembrane domain, CD28 intracellular domain, CD3ζ, and IRES, but is not limited thereto.
- The CD8 leader may include a nucleotide sequence of SEQ ID NO: 1, CD19 scFv may include a nucleotide sequence of SEQ ID NO: 2, MSLN scFv may include a nucleotide sequence of SEQ ID NO: 3, HER2 scFv may include a nucleotide sequence of SEQ ID NO: 4, CD8 hinge may include a nucleotide sequence of SEQ ID NO: 5, CD8 transmembrane domain may include a nucleotide sequence of SEQ ID NO: 6, Fc-γ receptor may include a nucleotide sequence of SEQ ID NO: 7, CD28 intracellular domain may include a nucleotide sequence of SEQ ID NO: 8, CD3ζ may include a nucleotide sequence of SEQ ID NO: 9, and the IRES inserted to clone the CAR gene into a vector constituting a double cistron may include a nucleotide sequence of SEQ ID NO: 10, but is not limited thereto.
- The CAR gene may further include GFP (green fluorescent protein), but is not limited thereto.
- The GFP may include a nucleotide sequence of SEQ ID NO: 11, but is not limited thereto.
- The nucleotide sequences of SEQ ID NO: 1 to SEQ ID NO: 11 can be confirmed from NCBI Genbank, a known database.
- In the present invention, the nucleotide sequences of SEQ ID NO: 1 to SEQ ID NO: 11 may include a nucleotide sequence having at least 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% or more homology or identity with SEQ ID NO: 1 to SEQ ID NO: 11. Additionally, it is apparent that a nucleotide sequence in which a part of the sequence is deleted, modified, substituted, or added may be included within the scope of the present invention as long as the nucleotide sequence has such homology or identity and exhibits a function corresponding to the nucleotide sequences of SEQ ID NO: 1 to SEQ ID NO: 11.
- As used herein, the term “homology and identity” refers to a degree of relatedness between two given amino acid sequences or nucleotide sequences, and may be expressed as a percentage. The terms homology and identity may often be used interchangeably with each other.
- The sequence homology or identity of conserved polynucleotides or polypeptide may be determined by standard alignment algorithms and can be used with a default gap penalty established by the program being used. Substantially, homologous or identical sequences are generally expected to hybridize to all or at least about 50%, 60%, 70%, 80%, or 90% or more of the entire length of the sequences under moderate or high stringent conditions. Polynucleotides that contain degenerate codons instead of codons in hybridizing polynucleotides are also considered.
- The homology or identity of the polypeptide or polynucleotide sequences may be determined by, for example, BLAST algorithm by literature [see Karlin and Altschul, Pro. Natl. Acad. Sci. USA, 90, 5873(1993)], or FASTA by Pearson (see Methods Enzymol., 183, 63, 1990). Based on the algorithm BLAST, a program referred to as BLASTN or BLASTX has been developed (see: http://www.ncbi.nlm.nih.gov). Further, whether any two amino add or polynucleotide sequences have a homology, similarity, or identity with each other may be identified by comparing the sequences in a Southern hybridization experiment under stringent conditions as defined, and appropriate hybridization conditions defined are within the skill of the art, and may be determined by a method well known to those skilled in the art (for example, J. Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989; F. M. Ausubel et al., Current Protocols in Molecular Biology).
- In the present invention, the CAR gene may be introduced into the cell in the same manner as the above-described method for introducing a reprogramming factor, and in particular, the reprogramming factor and the CAR gene may be introduced simultaneously or sequentially depending on a desired time and conditions.
- Specifically, as shown in blue of
FIG. 2 , the lentivirus expressing CAR may be transformed into PBMC at the time of conversion into iNK or into cells at the time of reprogramming induction process by inoculating into a culture medium selected from the steps of culturing in the CAR-iNK first medium, CAR-iNK second medium, or CAR-iNK third medium, simultaneously with the reprogramming factor or after introduction of the reprogramming factor. The method according to the present invention is significant in that CAR-expressing NK cells can be produced by introducing the CAR gene and the reprogramming factor into isolated cells other than NK cells. In addition, it is significant in that the time of introducing the CAR gene can be determined as desired by those skilled in the art during the reprogramming culturing process. Specifically, the time of introduction of the CAR gene, that is, the time of inoculation of the CAR-expressing lentivirus may be carried out simultaneously with the reprogramming factor (day 0), or at the step of culturing in the CAR-iNK second medium (day 12) or the CAR-iNK third medium (day 24) after introduction of the reprogramming factor, but is not limited thereto (FIGS. 2 and 6 ). - As used herein, the term “culture” means that the microorganism is grown under appropriately controlled environmental conditions. The culturing process of the present invention may be performed in a suitable culture medium and culture conditions known in the art. Such a culturing process may be easily adjusted for use by those skilled in the art according to the strain to be selected. For the purpose of the present invention, the culture is a process of converting cells into which reprogramming factors and/or CAR genes have been introduced into target cells of another lineage. The composition of the first medium, the second medium, or the third medium for culturing the cells into which the gene is introduced is a composition suitable for conversion into target cells, and for example, may include growth factors, cytokines, a GSK3β inhibitor, or an AHR antagonist, but is not limited thereto.
- The first medium of a) may include a growth factor, cytokines, and a GSK3β inhibitor.
- As used herein, the term “growth factor” means a polypeptide that promotes the division, growth, and differentiation of various cells. The growth factor may be, for example, EGF (epidermal growth factor), PDGF-AA (platelet-derived growth factor-AA), IGF-1 (insulin-like growth factor 1), TGF-β (transforming growth factor-β), FGF (fibroblast growth factors), SCF (stem cell factor), and FLT3 (FMS-like tyrosine kinase), and may specifically be any one or more selected from the group consisting of SCF, FLT3, and a combination thereof, but is not limited thereto.
- As used herein, the “cytokines” are various proteins of relatively small size that are produced in cells and used for cell signaling, and can affect other cells, including themselves. They are generally known to be involved in the immune response to inflammation or infection. The cytokines may be, for example, IL (interleukin)-2, IL-3, IL-5, IL-6, IL-7, IL-11, IL-15, IL-21, IL-12, IL-18, BMP4 (bone morphogenetic protein 4), activin A, notch ligand, G-CSF (granulocyte-colony stimulating factor), SDF-1 (stromal cell-derived factor-1), etc., and may specifically be any one or more selected from the group consisting of IL-3, IL-6 IL-15, IL-7, IL-2, IL-21, IL-12, IL-18, and a combination thereof, but are not limited thereto.
- For the purpose of the present invention, the growth factors and cytokines are included in the medium for directly reprogramming the isolated cells into the target cells, and the types of growth factors and cytokines are not particularly limited as long as they can be used for direct reprogramming.
- As used herein, the term “GSK3β (
glycogen synthase kinase 3 beta, glycogen synthase kinase-3β ) inhibitor” means a substance that suppresses or inhibits the activity of GSK3β. The GSK3β inhibitor may be, for example, 1-azakenpaullone, 2-D08, 3F8, 5-bromoindole, 6-Bio, A 1070722, aloisine A, AR-A014418, alsterpaullone, AZD-1080, AZD2858, bikinin, BIO, BIO-acetoxime, bisindolylmaleimide I, bisindolylmaleimide I hydrochloride, CAS 556813-39-9, cazpaullone, CHIR98014, CHIR98023, CHIR99021 (CT99021), CP21R7, dibromocantherelline, GSK-3β inhibitor I, VI, VII, X, XI, XV, GSK-3 inhibitor IX, XVI, hymenidin, hymenialdisine, HMK-32, I3M (indirubin-3-monoxime, indirubin, indole-3-acetamide, IM-12, kenpaullone, L803-mts, leucettine L41, lithium, lithium carbonate, LY-2090314, manzamine A MeBIO, meridianine A, NP00111, NP031115, NP031111, NSC 693868, palinurin, Ro 31-8220 methanesulfonate, SB-216763, SB-415286, TC-G 24, TCS 2002, TCS 21311, tideglusib, tricantin, trihydrochloride, tungstate, TWS-119, TZDZ-8, zinc, etc., and may specifically be CHIR99021, but is not limited thereto. - The first medium of a) may include SCF, FLT3, IL-3, and IL-6 and CHIR99021, but is not limited thereto.
- The first medium of a) may further include any one or more selected from the group consisting of fetal bovine serum (FBS), antibiotics, and a combination thereof, but is not limited thereto.
- The antibiotic may be penicillin/streptomycin, but is not limited thereto.
- Specifically, the first medium of a) may include FBS, penicillin/streptomycin, SCF, FLT3, IL-3, and IL-6 and CHIR99021, but is not limited thereto.
- More specifically, the first medium of a) may be StemSpan SFEM II containing 8% to 12% FBS, 0.1% to 2% penicillin/streptomycin, 80 ng/mL to 120 ng/mL human SCF, 80 ng/mL to 120 ng/mL human FLT3, 10 ng/mL to 30 ng/mL human IL-3, 10 ng/mL to 30 ng/mL human IL-6, and 2 μM to 7 μM CHIR99021, and more specifically StemSpan SFEM II containing 10% FBS, 1% penicillin/streptomycin, 100 ng/mL human SCF, 100 ng/mL human FLT3, 20 ng/mL human IL-3, 20 ng/mL human IL-6, and 5 μM CHIR99021, but is not limited thereto.
- The second medium of b) may include a growth factor, cytokines, and an AHR (aryl hydrocarbon receptor) antagonist.
- The terms “growth factor” and “cytokine” are the same as described above.
- As used herein, the term “AHR (aryl hydrocarbon receptor) antagonist” refers to a substance that down-regulates or reduces the activity of AHR, a ligand-activated transcription factor activated by TCDD (dioxin (2,3,7,8-tetrachlorodibenzo-p-dioxin)). The AHR antagonist may be, for example, StemRegenin I (SRI; 4-(2-((2-benzo[b]thiphen-3-yl)-9-isopropyl-9H-purin-6-yl)amino)ethyl)phenol hydrochloride], CH-223191(1-methyl-N-[2-methyl-4-[2-(2-methylphenyl)diazenyl]phenyl-1H-pyrazole-5-carboxamide), etc., and specifically StemRegenin I, but is not limited as long as it plays a role in increasing the efficiency of direct reprogramming.
- The second medium of b) may include SCF, FLT3, IL-15, IL-7, IL-2, and StemRegenin I, but is not limited thereto.
- The second medium of b) may further include any one or more selected from the group consisting of FBS, antibiotics, and a combination thereof, but is not limited thereto.
- The antibiotic may be penicillin/streptomycin, but is not limited thereto.
- Specifically, the second medium of b) may include FBS, penicillin/streptomycin, SCF, FLT3, IL-15, IL-7, IL-2, and StemRegenin I, but is not limited thereto.
- More specifically, the second medium of b) may include 8% to 12% FBS, 0.1% to 2% penicillin/streptomycin, 10 ng/mL to 30 ng/mL human SCF, 10 ng/mL to 30 ng/mL human FLT3, 100 IU/mL to 500 IU/mL human IL-2, 10 ng/mL to 30 ng/mL human IL-7, 10 ng/mL to 30 ng/mL human IL-15, and 1 μM to 3 μM StemRegenin I, and more specifically 10% FBS, 1% penicillin/streptomycin, 20 ng/mL human SCF, 20 ng/mL human FLT3, 200 IU/mL human IL-2, 20 ng/mL human IL-7, 20 ng/mL human IL-15, and 2 μM StemRegenin I, but is not limited thereto.
- The third medium of c) may include cytokines, a GSK3β inhibitor, and an AHR antagonist.
- The terms “cytokines”, “GSK3β inhibitor”, and “AHR antagonist” are the same as described above.
- The third medium of c) may include IL-2, IL-15, IL-21, IL-12, IL-18, CHIR99021, and StemRegenin I, but is not limited thereto.
- The third medium of c) may further include any one or more selected from the group consisting of FBS, antibiotics, and a combination thereof, but is not limited thereto.
- The antibiotic may be penicillin/streptomycin, but is not limited thereto.
- Specifically, the third medium of c) may include FBS, penicillin/streptomycin, IL-2, IL-15, IL-21, IL-12, IL-18, CHIR99021, and StemRegenin I, but is not limited thereto.
- More specifically, the third medium of c) may be RPMI 1640 containing 8% to 12% FBS, 0.1% to 2% penicillin/streptomycin, 100 IU/mL to 500 IU/mL human IL-2, 40 ng/mL to 60 ng/mL human IL-12, 10 ng/mL to 30 ng/mL human IL-15, 90 ng/mL to 110 ng/mL human IL-18, 10 ng/mL to 30 ng/mL human IL-21, 1 μM to 3 μM CHIR99021, and 1 μM to 3 μM StemRegenin I, and more specifically RPMI 1640 containing 10% FBS, 1% penicillin/streptomycin, 200 IU/mL human IL-2, 50 ng/mL human IL-12, 20 ng/mL human IL-15, 100 ng/mL human IL-18, 20 ng/mL human IL-21, 2 μM CHIR99021, and 2 μM StemRegenin I, but is not limited thereto.
- In the method above, the isolated cells into which the reprogramming factor and the CAR gene are introduced may be cultured in the first medium of a) for 4 to 7 days, and in the second medium of b) for 10 to 14 days, and then in the third medium of c) for 14 days or more, but is not limited thereto.
- In one embodiment of the present invention, the cells were cultured for different culture periods (3, 5, 7, and 9 days) in the CAR-iNK first medium, and then cultured in the CAR-iNK second medium and the third medium under the same conditions as in Example 1, and the CAR-iNK production yield was analyzed by comparison. As a result, it was confirmed that the highest CAR-iNK production yield of about 80% was obtained when the cells were cultured in the CAR-iNK first medium for 5 days (
FIG. 7A ). - In another embodiment of the present invention, it was confirmed that the CAR-iNK yield efficiency was increased when the cells were cultured in the CAR-iNK third medium containing 20 ng/mL human IL-21, 2 μM CHIR99021, 2 μM StemRegenin I (SR1), 50 ng/mL human IL-12, and 100 ng/mL human IL-18 (
FIG. 7B ). In addition, when the cells were cultured for 7 days or 14 days in the CAR-iNK third medium for each composition, it was confirmed that the CAR-iNK yield efficiency was increased up to 15 times when cultured for 14 days (FIG. 7B ). This suggested that CAR-iNK cells exhibited the highest production efficiency (CD19-CAR-iNK cells: maximum 45.9% (FIG. 6A ), MSLN-CAR-iNK cells: 43.7% (FIG. 4 )), HER2-CAR-iNK cells: 47.8% (FIG. 5 ) when cultured in the CAR-iNK first medium for 5 days, in the CAR-iNK second medium for 12 days, and in the CAR-iNK third medium for 2 to 3 weeks. - The CAR-iNK cells produced according to the method of the present invention may express any one or more selected from the group consisting of CD56+, CD16+, CD3−, and a combination thereof, but is not limited thereto.
- The “CD56+”, “CD16+”, and “CD3−” are indicators on the surface of NK cells, and in the present invention, the expression of CD56+, CD16+, and CD3− was analyzed through flow cytometry to determine whether CAR-iNK cells were produced (
FIGS. 3 to 6 ). - In addition, the CAR-iNK cells produced according to the method of the present invention may have an excellent killing ability against various cancer cells.
- In one embodiment of the present invention, the frequency (%) of CD107a+ cells and interferon-gamma+cells having an cancer cell lysis ability was increased in cancer cells co-cultured with the CAR-iNK cells (
FIGS. 8 to 15 ), and as a result of confirming the killing ability of iNK cells against blood cancer cell lines, pancreatic cancer cell lines, prostate cancer cell lines, colorectal cancer cell lines, lung cancer cell lines, liver cancer cell lines, gastric cancer cell lines, and melanoma cell lines, it was confirmed that they exhibited an excellent killing ability (FIGS. 16 to 18 ). Additionally, it was confirmed that the tumor size was significantly reduced on the 14th day after the injection of CAR-iNK cells in a mouse model with pancreatic cancer, compared to the control group which was not injected with iNK cells or iNK cells into which the CAR gene was not introduced (FIG. 19 ). - Another aspect of the present invention provides CAR-iNK cells produced according to the method above. The terms used herein are the same as described above.
- As described above, the CAR-iNK cells may have an excellent killing ability against various cancer cells.
- Still another aspect of the present invention provides a cell therapy composition for preventing or treating cancer, including the CAR-iNK cells produced according to the method above, as an active ingredient.
- The terms used herein are the same as described above.
- As used herein, the term “prevention” refers to all actions that suppress or delay cancer by the administration of the composition.
- As used herein, the term “treatment” refers to all actions that alleviate or beneficially change the symptoms of cancer by the administration of the composition.
- As used herein, the term “cell therapeutic agent” refers to a drug for treatment, diagnosis, and prevention (U.S. FDA guidance) containing cells or tissues prepared from humans via isolation, culture, and specialized manipulations, and to a drug for treatment, diagnosis, and prevention prepared by any process including proliferating and selecting autologous, homologous, or heterologous cells ex vivo, or modifying the biological characteristics of cells, so as to restore the function of cells or tissues.
- The cell therapy composition may have an efficacy of preventing or treating cancer by including the CAR-iNK cells produced according to the method of the present invention.
- The cell therapy composition may contain the CAR-iNK cells at 1.0×104 cells/mL to 1.0×1010 cells/mL, preferably 1.0×105 cells/mL to 1.0×109 cells/mL, based on the total weight of the composition, but is not limited thereto.
- The cell therapy composition may be administered by formulating it into a pharmaceutical formulation in the form of unit dosage suitable for administration to the body of a patient by conventional methods in the pharmaceutical field, and it contains an effective amount by a single dose or in divided doses. For this purpose, a formulation for parenteral administration may preferably include injection formulation such as an injection ampoule, infusion formulation such as an infusion bag, and spray formulation such as an aerosol, etc. The injection ampoule may be mixed with injection solution such as saline solution, glucose, mannitol, and Ringer's solution just before use. Further, the cells can be carried by an infusion bag textured with polyvinyl chloride or polyethylene, and examples thereof may include infusion bags manufactured by Baxter, Becton Dickinson, Medcep, National Hospital Products, or Terumo.
- The pharmaceutical formulation may additionally include one or more pharmaceutically acceptable inactive carriers in addition to the active ingredient, for example, a preservative, analgesic controller, solubilizer, or stabilizer for injection formulation, and a base, excipient, lubricant, or preservative for topical formulation.
- The thus-produced cell therapy composition of the present invention or a pharmaceutical formulation thereof may be administered in accordance with any conventional method in the art together with other cells used for treatment of cancer, or in the form of a mixture therewith. Direct engraftment or transplantation to the diseased area of a patient in need of treatment, or direct transplantation or injection into the abdominal cavity is preferred, but the method is not limited thereto. Further, both non-surgical administration using a catheter and surgical administration such as injection or transplantation after incision of the diseased area are possible. In addition, the composition may also be administered parenterally by the conventional method, for example, transplantation of cells into the hematopoietic system, in addition to direct administration to the lesion.
- The cell therapy composition of the present invention may be administered in an amount ranging from about 0.0001 mg/kg to 1000 mg/kg, preferably 0.001 mg/kg to 100 mg/kg once per day or in several divided doses per day. However, it should be understood that the amount of the active ingredient actually administered ought to be determined in light of various relevant factors including the disease to be treated, the severity of the disease, the route of administration, and the body weight, age and sex of a patient, and therefore, the above dose should not be intended to limit the scope of the present invention in any way.
- Yet another aspect of the present invention provides a pharmaceutical composition for preventing or treating cancer, including the CAR-iNK cells produced according to the method above, as an active ingredient.
- The terms used herein are the same as described above.
- In the present invention, the cancer may be a cancer showing prevention or treatment results due to an immune response of CAR-iNK cells, etc. The cancer may be, for example fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma cancer, osteogenic sarcoma, myeloma, myeloma, myelodysplasia, lymphoma, non-Hodgkin's lymphoma, blood cancer, melanoma, chordoma, angiosarcoma, endothelial sarcoma, lymphangiosarcoma, lymphangioendothelioma, synovial sarcoma, mesothelioma, Ewing's sarcoma, gastric cancer, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, colon cancer, colorectal cancer, rectal cancer, pancreatic cholangiocarcinoma, pancreatic cancer, biliary tract cancer, gallbladder cancer, liver cancer, breast cancer, ovarian cancer, uterine cancer, prostate cancer, preleukemia, leukemia, acute leukemia, B-cell acute lymphoblastic leukemia (BALL), T-cell acute lymphoblastic leukemia (TALL), small lymphocytic leukemia (SLL), acute lymphoblastic leukemia (ALL); chronic leukemia, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous adenocarcinoma, papillary thyroid cancer, cyst cancer, medullary thyroid cancer, bronchogenic carcinoma, renal cell carcinoma, liver cancer, biliary duct carcinoma, choriocarcinoma, seminoma, embryonic carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, lung cancer, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, head and neck cancer, brain cancer, glioma, astrocytoma, renal cell carcinoma, glioblastoma, medulloblastoma, craniopharyngioma, ependymoma, pineal gland tumor, hemangioblastoma, acoustic neuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, retinoblastoma, and sarcoma, and may specifically be a cancer associated with expression of any one or more of CD19, MSLN, or HER2, for example, any one or more selected from the group consisting of myelodysplasia, myelodysplastic syndrome, preleukemia, blood cancer, acute leukemia, B-cell acute lymphoblastic leukemia (BALL), T-cell acute lymphoblastic leukemia (TALL), small lymphocytic leukemia (SLL), acute lymphoblastic leukemia (ALL), chronic leukemia, chronic myelogenous leukemia (CML), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma, lymphoma, myeloma, pancreatic cancer, biliary tract cancer, lung cancer, ovarian cancer, breast cancer, uterine cancer, rectal cancer, colorectal cancer, colon cancer, bone marrow cancer, liver cancer, brain cancer, prostate cancer, stomach cancer, glioma, melanoma, squamous cell carcinoma, head and neck cancer, renal cell cancer, glioblastoma, medulloblastoma, sarcoma, and a combination thereof, and more specifically any one or more selected from the group consisting of blood cancer, pancreatic cancer, prostate cancer, colorectal cancer, lung cancer, liver cancer, stomach cancer, melanoma, and a combination thereof, but is not limited thereto.
- The pharmaceutical composition may have an efficacy of preventing or treating cancer by including the CAR-iNK cells produced according to the method of the present invention.
- The pharmaceutical composition of the present invention may contain the CAR-iNK cells at 1.0×104 cells/mL to 1.0×1010 cells/mL, preferably 1.0×105 cells/mL to 1.0×109 cells/mL, based on the total weight of the composition, but is not limited thereto.
- The pharmaceutical composition may further include a pharmaceutically acceptable carrier, excipient or diluent commonly used in the preparation of the pharmaceutical compositions, and the carrier may include a carrier which does not occur naturally. The carriers, excipients, and diluents may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and minerals.
- Further, the pharmaceutical composition may be formulated according to a conventional method into a tablet, a pill, a powder, a granule, a capsule, a suspension, a solution for internal use, an emulsion, a syrup, a sterilized aqueous solution, a non-aqueous solution, a suspension, an emulsion, a lyophilized preparation, a transdermal preparation, a gel, a lotion, an ointment, a cream, a patch, a cataplasma form, a paste, a spray, a skin emulsion, a skin suspension, a transdermal patch, a drug-containing bandage, or a suppository for use.
- Specifically, the preparation may be formulated with commonly used diluents or excipients, such as fillers, extenders, binders, wetting agents, disintegrants, surfactants, etc. Solid formulations for oral administration may include tablets, pills, powders, granules, capsules, etc., but are not limited thereto. Such solid formulations may be prepared by mixing with at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate or talc may also be used. Liquid formulations for oral administration may be prepared by adding various excipients, for example, wetting agents, flavoring agents, aromatics, preservatives, etc. in addition to liquid paraffin. Formulations for parenteral administration may include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. The non-aqueous solutions and the suspensions may include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyloleate, etc. The base for suppositories may include witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin, etc.
- The pharmaceutical composition of the present invention may be administered in a pharmaceutically effective amount. As used herein, the term “pharmaceutically effective amount” means an amount which is sufficient to treat diseases at a reasonable benefit/risk ratio applicable to any medical treatment. The effective dosage level may be determined depending on factors including a kind of a subject and severity, age, sex, activity of a drug, drug sensitivity, administration time, administration route, excretion rate, duration of treatment, drugs used concurrently, and other factors known in the medical field. For example, the pharmaceutical composition may be administered in a daily dosage of 0.0001 mg/kg to 1000 mg/kg, and specifically 0.001 mg/kg to 100 mg/kg, and the dose may be administered once per day or in several divided doses per day.
- The pharmaceutical composition may be administered alone as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with existing therapeutic agents. The composition may be administered in a single or multiple dosage form. It is important to administer the composition in a minimum amount that may exhibit a maximum effect without causing side effects, considering all of the above-described factors. The amount may be readily determined by those skilled in the art.
- As used herein, the term “administration” means introducing the composition of the present invention into a subject by any suitable method. The administration route of the composition may be administered through any general route as long as it can reach the target tissue, including intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, and intranasal administration, but is not limited thereto.
- As used herein, the term “subject” refers to any animal, including humans, monkeys, cattle, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits or guinea pigs having cancer or at risk of having cancer. As long as the disease can be effectively prevented or treated by administering the pharmaceutical composition of the present invention into a subject, any type of subject may be included without limitation.
- Even another aspect of the present invention provides a method for treating cancer, including administering the cell therapy composition or the pharmaceutical composition to a subject except a human.
- The terms used herein are the same as described above.
- The present invention provides a simplified production process because CAR-iNK cells are produced from isolated cells through direct reprogramming and a production time of at least 32 days, which is shorter than that obtained by the method in which the CAR gene was introduced after producing NK cells using conventional reprogramming techniques, thereby reducing costs, has excellent NK cell production efficiency of 47.8% at maximum, and ensures safety as the cells are produced without passing through pluripotent stem cells, thereby showing an excellent CAR-iNK cell production effect that is distinguished from that of the conventional reprogramming techniques.
- In addition, the present invention is distinguished from the conventional method of obtaining NK cells through direct harvesting, stem cell differentiation, etc. in that NK cells can be directly produced by culturing cells, which have a different cell lineage from NK cells and are easy to collect, in a reprogramming medium, and thus, the present invention is meaningful in that it can provide a wide range of options for cell types and quality.
- Further, the CAR-iNK cells produced according to the method of the present invention have an excellent cancer cell killing ability as described above, and thus can be provided as a cell therapy composition and a pharmaceutical composition for preventing or treating cancer including the same.
- Hereinafter, the constitution and effect of the present invention will be described by way of specific Examples. However, these Examples are provided for illustrative purposes only, and the scope of the invention is not intended to be limited by these Examples.
- In order to construct double cistron lentiviral vectors encoding CAR (chimeric antigen receptor), four CAR genes each binding to CD19, HER2, (human epidermal growth factor receptor 2) or MSLN (mesothelin) were constructed. Each of the above CAR genes was constructed to include genes encoding an extracellular domain, a transmembrane domain, and an intracellular domain including an antibody domain (scFv). Specifically, each of the CAR genes was constructed as follows (
FIG. 1 ): - i) CD19-CAR1 gene including CD8 leader (SEQ ID NO: 1), CD19 scFv (SEQ ID NO: 2), CD8 hinge (SEQ ID NO: 5), CD8 transmembrane (TM) domain (SEQ ID NO: 6), Fc-γ (gamma) receptor (SEQ ID NO: 7), and GFP (green fluorescent protein) (SEQ ID NO: 11);
- ii) CD19-CAR2 gene including CD8 leader (SEQ ID NO: 1), CD19 scFv (SEQ ID NO: 2), CD8 hinge (SEQ ID NO: 5), CD8 transmembrane domain (SEQ ID NO: 6), CD28 intracellular domain (SEQ ID NO: 8), CD3 (zeta) (SEQ ID NO: 9), IRES (internal ribosome entry site) (SEQ ID NO: 10), and GFP (SEQ ID NO: 11);
- iii) MSLN-CAR gene including CD8 leader (SEQ ID NO: 1), MSLN (mesothelin) scFv (SEQ ID NO: 3), CD8 hinge (SEQ ID NO: 5), CD8 transmembrane domain (SEQ ID NO: 6), CD28 intracellular domain (SEQ ID NO: 8), CD3 (SEQ ID NO: 9), IRES (SEQ ID NO: 10), and GFP (SEQ ID NO: 11); and
- iv) HER2-CAR gene including CD8 leader (SEQ ID NO: 1), HER2 (human epidermal growth factor receptor 2) scFv (SEQ ID NO: 4), CD8 hinge (SEQ ID NO: 5), CD8 transmembrane domain (SEQ ID NO: 6), CD28 intracellular domain (SEQ ID NO: 8), CD3 (SEQ ID NO: 9), IRES (SEQ ID NO: 10), and GFP (SEQ ID NO: 11).
- The IRES was inserted for cloning the CAR gene into a vector constituting a double cistron. For each vector containing the four CAR genes, each domain of
FIG. 1 was synthesized from CAR1 (Addgene ID: 113014), and CAR-expressing lentiviruses were constructed through overlap PCR (Gibson assembly). - Isolated peripheral blood mononuclear cells (PBMC) were cultured for 4 days in the culture solution (Stempro SFEM II containing 2.5% Stem Pro-34 nutrient supplement, 2 mM Glutamax I, 1% penicillin/streptomycin, 20 ng/mL human IL (interleukin)-3, 20 ng/mL human IL-6, 100 ng/mL human stem cell factor (SCF), and 100 ng/mL human FLT3 (FMS-like tyrosine kinase)), while changing the medium once every 2 days.
- In order to transform the reprogramming factors (Oct4, Sox2, Klf4, and Myc) into the PBMC, the Sendai virus system [Oct4, Sox2, Klf4, and Myc-expressing RNA-based Sendai virus (CytoTune 2.0 Sendai Reprogramming Kit, Thermo Scientific); OSKM-SeV] expressing the reprogramming factors and the 4 types of lentiviruses expressing the 4 types of CARs of Example 1 were used. Specifically, in order to transform PBMC with the reprogramming factors, the cells were cultured in a standard culture medium (SCM medium) containing the Sendai virus (5 MOI), PBMC and polybrene (4 μg/mL) for 1 day, and then sequentially cultured in the first medium, second medium, and third medium shown below. The cells transformed by the method (2×105 cells/48-well plate) were cultured in the first CAR-iNK medium (StemSpan SFEM II containing 10% FBS, 1% penicillin/streptomycin, 100 ng/mL human SCF, 100 ng/mL human FLT3, 20 ng/mL human IL-3, 20 ng/mL human IL-6, and 5 μM CHIR99021) including the GSK3β (glycogen synthase kinase 3β) inhibitor for 5 to 6 days, and then cultured in the CAR-iNK second medium (StemSpan SFEM II containing 10% FBS, 1% penicillin/streptomycin, 20 ng/mL human SCF, 20 ng/mL human FLT3, 200 IU/mL human IL-2, 20 ng/mL human IL-7, 20 ng/mL human IL-15, and 2 μM StemRegenin I) including the AHR (aryl hydrocarbon receptor) antagonist for 12 days, and subsequently in the CAR-iNK third medium (RPMI 1640 containing 10% FBS, 1% penicillin/streptomycin, 200 IU/mL human IL-2, 50 ng/mL human IL-12, 20 ng/mL human IL-15, 100 ng/mL human IL-18, 20 ng/mL human IL-21, 2 μM CHIR99021, and 2 μM StemRegenin I) including the GSK3β inhibitor and AHR antagonist for 14 days or more to induce the cells into NK cells (
FIG. 2 ). The CAR-expressing lentiviruses were inoculated into a culture medium selected from the step of culturing in the CAR-iNK first medium (day 4), the CAR-iNK second medium (day 14), or the CAR-iNK third medium (day 24) simultaneously with the reprogramming factor (day 0) or after introduction of the reprogramming factor, as shown inFIG. 2 , and thus were transformed into the cells during the reprograming process by which PBMC were converted into NK cells. - In order to confirm whether NK cells introduced with the CD19-CAR1 gene, CD19-CAR2 gene, MSLN-CAR gene, or HER2-CAR gene were prepared through the direct reprogramming, the cells were stained with the CD56 antibody, CD3 antibody, CD19 antigen, MSLN antigen, and HER2 antigen, and then iNK cell group (CD56+ and CD3−), CD19 CAR-iNK cell group (CD56+ and CD19+), MSLN CAR-iNK cell group (CD56+and MSLN+), and HER2 CAR-iNK cell group (CD56+and HER2+) were analyzed using flow cytometry. Specifically, NK (iNK) cells induced through direct reprogramming were added to a phosphate buffer (FACS buffer) containing 1% BSA (bovine serum albumin) and 2 mM EDTA (ethylenediaminetetraacetic acid), supplemented with fluorescent-labeled antibodies and antigens, and reacted at room temperature for 20 minutes, and subsequently, the cells were washed and recovered using a centrifuge, and then analyzed by FACS (BD Bioscience).
- In addition, in order to confirm whether each CAR gene was inserted into the genome of iNK cells, the genomic DNA of each cell was analyzed with primers (SEQ ID NOS: 12 and 13) for CD19 CAR, primers (SEQ ID NOS: 14 and 15) for MSLN CAR, and primers (SEQ ID NOS: 16 and 17) for HER2 CAR through PCR gene analysis.
- As a result, it was confirmed that CD56+CD3−CD19-CAR-iNK cells were produced with a maximum efficiency of 45.9% (
FIG. 3 andFIG. 6A ), that CD56+CD3−MSLN-CAR-iNK were produced with a maximum efficiency of 43.7% (FIG. 4 ), and that CD56+CD3− HER2-CAR-iNK cells were produced with a maximum efficiency of 47.8% (FIG. 5 ). - Further, as shown in
FIG. 6 , when the CAR-expressing lentiviruses were inoculated into a culture medium selected from the step of culturing in the CAR-iNK second medium (day 14) or CAR-iNK third medium (day 24), simultaneously with the reprogramming factor (day 0) or after introduction of the reprogramming factor, it was confirmed that CD56+CD3−CD19-CAR-iNK cells were produced with an efficiency of 15.5%, 31.6%, and 45.9%. - 3-1. Optimization of Incubation Period in CAR-iNK First Medium
- The cells were cultured in the CAR-iNK first medium for different incubation periods (3, 5, 7, and 9 days), and then cultured in the CAR-iNK second medium and the third medium under the same conditions as in Example 1, and the CAR-iNK production yield was analyzed by comparison.
- As a result, it was confirmed that the highest CAR-iNK production yield of about 80% was obtained when cultured in the CAR-iNK first medium for 5 days (
FIG. 7A ). - 3-2. Optimization of Composition of CAR-iNK Third Medium The CAR-iNK production yield was analyzed by comparison by culturing in the CAR-iNK first medium and the second medium under the same conditions as in Example 1, and then cultured in the CAR-iNK third medium having different compositions.
- As a result, it was confirmed that the CAR-iNK yield efficiency was increased when cultured in the CAR-iNK third medium containing 20 ng/mL human IL-21, 2 μM CHIR99021, 2 μM StemRegenin 1 (SR1), 50 ng/mL human IL-12, and 100 ng/mL human IL-18 (
FIG. 7B ). In addition, it was confirmed that in the case of culturing the cells for 7 days or 14 days in the CAR-iNK third medium for each composition, the CAR-iNK yield efficiency was increased up to 15 times when cultured for 14 days (FIG. 7B ). - Based on the above results, the CAR-iNK cells were cultured in the CAR-iNK first medium for 5 days, in the CAR-iNK second medium for 12 days, and in the CAR-iNK third medium for 2 to 3 weeks.
- In order to verify the cancer cell killing potential of the CAR-iNK cells produced in Example 2, the frequency of CD107a+cells having a cancer cell lysis ability, which are expressed after co-culturing CAR-iNK cells with cancer cells, was quantitatively analyzed. Specifically, 1 ×106 cells/mL of Raji (Raji B, human B lymphocytes; Burkitt's lymphoma), Jurkat T (immortalized human T lymphocytes), SNU-291 (human B-lymphoblastoid cells), SNU-817 (human B-lymphoblastoid cells), HCT116 (human colon cancer cells), NIC-H460 (human lung cancer cells), HepG2 (human liver hepatocellular carcinoma cells), Mia-paca-2 (human pancreas ductal adenocarcinoma cells), PC3 (PC-3, human prostate cancer cells), which are cancer cells, and 1×106 cells/mL of CAR-iNK cells were each dispensed in a 6-well plate in an amount of 1 mL, and centrifuged at 400 g for 1 minute, followed by culturing in a cell incubator at 37° C. in the presence of 5% CO2 for 2 hours or 16 hours, and then the frequency of CD107a+ cells was confirmed through flow cytometry. Specifically, the frequency of CD107a+ cells was determined through FACS analysis after reacting the CAR-iNK cells in FACS buffer supplemented with fluorescent-labeled antibodies against CD56 and CD107a at room temperature for 20 minutes, and then washing and recovering the cells using a centrifuge.
- As a result, when the cancer cells were co-cultured with CD19-CAR-iNK cells (
FIGS. 8 and 9 ), MSLN-CAR-iNK cells (FIG. 10 ), and HER2-CAR-iNK cells (FIG. 11 ), it was confirmed that the frequency (%) of CD107a+iNK cells was increased, compared to the iNK control group into which the CAR gene was not introduced or the control group (−) without co-cultivation. - In order to verify the cancer cell killing potential of the CAR-iNK cells produced in Example 2, the frequency of IFN-gamma cells, which are expressed after co-culturing CAR-iNK cells with cancer cells, was quantitatively analyzed. Specifically, 1 ×106 cells/mL of Raji, SNU-291, SNU-817, HepG2, NIC-H460 (human lung cancer cells), KATO3 (KATOIII, human gastric cancer cells), CFPAC-1 (human ductal pancreatic adenocarcinoma cells), and 1×106 cells/mL of CAR-iNK cells were each dispensed in a 6-well plate in an amount of 1 mL, and centrifuged at 400 g for 1 minute, followed by culturing in a cell incubator at 37° C. in the presence of 5% CO2 for 2 hours or 16 hours, and then the frequency of IFN-gamma cells was confirmed through flow cytometry. Specifically, the frequency of IFN-gamma cells was determined after reacting the CAR-iNK cells in a phosphate buffer containing 0.5
% Tween 20 and 0.5% BSA at room temperature for 20 minutes, and then washing and recovering the cells using a centrifuge. The recovered cells were reacted at room temperature for 20 minutes in FACS buffer supplemented with fluorescent-labeled antibodies against CD56 and IFN-gamma, and then the cells were washed and recovered using a centrifuge and subjected to FACS analysis. - As a result, it was confirmed that the frequency (%) of IFN-gamma+iNK cells was increased when the cancer cells were co-cultured with CD19-CAR-iNK cells (
FIGS. 12 and 13 ), MSLN-CAR-iNK cells (FIG. 14 ), and HER2-CAR-iNK cells (FIG. 15 ), compared to the iNK control group into which the CAR gene was not introduced or the control group (−) without co-cultivation. - In order to measure the cancer cell killing ability of the CAR-iNK cells produced in Example 1, the cell killing ability was measured using calcein-AM. Specifically, Raji, SNU-291, SNU-817, Mia-paca-2, CFPAC-1, PC3 (PC-3), LNcap (androgen-sensitive human prostate adenocarcinoma cells), DU145 (human prostate cancer cells), HCT116, A549 (human lung carcinoma cells), NIC-H460, HepG2, KATO3 (KATOIII), SK-MEL-3 (human melanoma cells), which are cancer cells, were diluted to 1×105 cells/mL in DMEM medium containing 10% fetal bovine serum, added with calcein-AM to a concentration of 25 μM, and washed with DMEM medium after culturing for 1 hour at 37° C., and accordingly, calcein-labeled target cancer cells were prepared.
- The iNK cells were prepared by diluting the cells to a density of 0.25×105 cells/mL and 1 ×105 cells/mL using a culture solution, and then dispended in a 96-well plate in an amount of 100 mL. The thus-prepared calcein-labeled target cancer cells (1×105 cells/mL) were added to a 96-well plate in an amount of 100 pUwell, centrifuged at 400 g for 1 minute, and then cultured in a cell incubator at 37° C. for 4 hours in the presence of 5% CO2, and subsequently, 100 μL of the supernatant was taken from each well and measured with a fluorescence plater reader (485 nm/535 nm). The cell killing ability (%) was calculated according to the following formula.
-
Cancer Cell Killing Ability(%)={(Measured ValueΔMinimum Value)/(Measured Value−Minimum Value)}×100 - In the above formula, the minimum value is the measured value of a well in which only calcein-labeled target cancer cells exist, and the maximum value is the measured value of a well in which cells are completely lysed by adding 0.1% TritonX-100 to the calcein-labeled target cancer cells.
- As a result, it was confirmed that CD19-CAR-iNK cells (
FIG. 16 ), MSLN-CAR-iNK cells (FIG. 17 ), and HER2-CAR-iNK cells (FIG. 18 ) exhibited a high cancer cell killing ability, compared to iNK control group, and that the cancer cell killing ability was increased in proportion to the number of iNK cells. - 200 μL (1×107 cells/mL) of CFPAC-1 expressing luciferase were subcutaneously injected into the back of 8-week-old nude mice (Balb/c-nude mice, average weight 20-25 g) to prepare a pancreatic cancer cell xenograft mouse animal model. The next day, after injecting 200 μL of PBS as a negative control, or iNK and MSLN-CAR-iNK cells as an experimental group at the same dose (1 ×107 cells/mL PBS), 150 μL of D-luciferin dissolved in PBS was injected intraperitoneally at 7-day intervals (150 μg/mL, Promega), and the tumor size was confirmed through IVIS 100 (PerkinElmer) after 15 to 20 minutes.
- As a result, it was confirmed that the tumor size formed in the iNK (5.35×109 radiance) and CAR-NK (3.83×109 radiance) cell experimental groups was significantly reduced compared to the tumor size (1.21 ×1010 radiance) of the control group formed under the condition of PBS injection on the 14th day, thereby confirming that the CAR-iNK cells exhibited an excellent anticancer effect compared to iNK cells (
FIG. 19 ). - From the results of the above Examples, it was confirmed that the CAR-iNK cells having an excellent anticancer ability can be prepared by directly reprogramming the isolated cells.
- Those of ordinary skill in the art will recognize that the present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The scope of the present invention is therefore indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within the scope of the present invention.
Claims (21)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0036264 | 2019-03-28 | ||
KR20190036265 | 2019-03-28 | ||
KR20190036264 | 2019-03-28 | ||
KR10-2019-0036265 | 2019-03-28 | ||
PCT/KR2020/004197 WO2020197318A1 (en) | 2019-03-28 | 2020-03-27 | Method for producing nk cells with car gene introduced thereto, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220184128A1 true US20220184128A1 (en) | 2022-06-16 |
Family
ID=72610717
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/598,917 Pending US20220160769A1 (en) | 2019-03-28 | 2020-03-27 | Method for producing immunocytes, and use thereof |
US17/598,916 Pending US20220184128A1 (en) | 2019-03-28 | 2020-03-27 | Method for producing car gene-introduced nk cells and use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/598,917 Pending US20220160769A1 (en) | 2019-03-28 | 2020-03-27 | Method for producing immunocytes, and use thereof |
Country Status (6)
Country | Link |
---|---|
US (2) | US20220160769A1 (en) |
EP (2) | EP3954762A4 (en) |
JP (3) | JP2022527932A (en) |
KR (2) | KR102298639B1 (en) |
CN (2) | CN113874492B (en) |
WO (2) | WO2020197319A1 (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112656789A (en) * | 2020-12-31 | 2021-04-16 | 中国科学院生态环境研究中心 | Application of FICZ in inhibiting tumor cell migration |
WO2023038475A1 (en) * | 2021-09-10 | 2023-03-16 | 한국생명공학연구원 | Method for producing directly reprogrammed natural killer cells and use thereof |
KR20230039789A (en) * | 2021-09-10 | 2023-03-21 | 한국생명공학연구원 | Method for producing induced natural killer cells and their use for preventing or treating infectious diseases |
WO2023090780A1 (en) * | 2021-11-22 | 2023-05-25 | 재단법인 아산사회복지재단 | Natural killer cell-specific chimeric antigen receptor and use thereof |
CN114350608B (en) * | 2022-01-27 | 2024-05-28 | 昭泰英基生物医药(香港)有限公司 | Composition for inducing T cells to be reprogrammed into NK-like cells and application thereof |
CN114958771B (en) * | 2022-06-27 | 2023-12-05 | 广东康盾创新产业集团股份公司 | Preparation method of IPSC-CAR-NK cells |
KR20240066123A (en) | 2022-11-07 | 2024-05-14 | 마루테라퓨틱스 주식회사 | Culture method to increase differentiation efficiency and functionality of NK cells |
CN115804776A (en) * | 2022-12-16 | 2023-03-17 | 国纳之星(上海)纳米科技发展有限公司 | Application of aromatic hydrocarbon receptor inhibitor and 5-fluorouracil in combination in tumor treatment and inhibition drugs |
CN117660335A (en) * | 2023-12-14 | 2024-03-08 | 广州百康细胞生命科技有限公司 | Method for converting somatic cells into immune cells by using chemical reediting method |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2754394T3 (en) * | 2010-09-08 | 2020-04-17 | Chemotherapeutisches Forschungsinstitut Georg Speyer Haus | Chimeric antigen receptors with an optimized hinge region |
EP2841563B1 (en) * | 2012-04-24 | 2019-06-12 | Dan S. Kaufman | Method for developing natural killer cells from stem cells |
KR101550269B1 (en) * | 2014-01-22 | 2015-09-07 | 한국생명공학연구원 | A method for direct dedifferentiation of hematopoietic stem cell from fibroblast cell |
KR20160145186A (en) * | 2014-04-24 | 2016-12-19 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | Application of induced pluripotent stem cells to generate adoptive cell therapy products |
WO2016109661A1 (en) * | 2014-12-31 | 2016-07-07 | Anthrogenesis Corporation | Natural killer cells and uses thereof |
CN106349389B (en) * | 2015-07-21 | 2019-11-15 | 科济生物医药(上海)有限公司 | Tumour-specific anti-egfr antibodies and its application |
WO2017070337A1 (en) * | 2015-10-20 | 2017-04-27 | Cellular Dynamics International, Inc. | Methods for directed differentiation of pluripotent stem cells to immune cells |
EP3474867A4 (en) * | 2016-06-24 | 2020-05-20 | iCell Gene Therapeutics LLC | Chimeric antigen receptors (cars), compositions and methods thereof |
JP7181219B2 (en) * | 2017-04-18 | 2022-11-30 | フジフィルム セルラー ダイナミクス,インコーポレイテッド | antigen-specific immune effector cells |
CN107384949B (en) * | 2017-06-27 | 2019-01-15 | 闾民 | Express iNKT cell and the preparation, application of GPC3 Chimeric antigen receptor |
KR102167548B1 (en) * | 2017-09-21 | 2020-10-19 | 한국생명공학연구원 | A method for producing natural killer cells and uses thereof |
WO2019059713A2 (en) * | 2017-09-21 | 2019-03-28 | 한국생명공학연구원 | Method for producing natural killer cell and use thereof |
-
2020
- 2020-03-27 US US17/598,917 patent/US20220160769A1/en active Pending
- 2020-03-27 KR KR1020200037718A patent/KR102298639B1/en active IP Right Grant
- 2020-03-27 KR KR1020200037719A patent/KR102298640B1/en active IP Right Grant
- 2020-03-27 US US17/598,916 patent/US20220184128A1/en active Pending
- 2020-03-27 CN CN202080038913.6A patent/CN113874492B/en active Active
- 2020-03-27 JP JP2021557871A patent/JP2022527932A/en active Pending
- 2020-03-27 EP EP20778116.2A patent/EP3954762A4/en active Pending
- 2020-03-27 EP EP20777770.7A patent/EP3950935A4/en active Pending
- 2020-03-27 CN CN202080038941.8A patent/CN113874493B/en active Active
- 2020-03-27 WO PCT/KR2020/004198 patent/WO2020197319A1/en unknown
- 2020-03-27 JP JP2021557872A patent/JP7429713B2/en active Active
- 2020-03-27 WO PCT/KR2020/004197 patent/WO2020197318A1/en unknown
-
2023
- 2023-09-25 JP JP2023160032A patent/JP2023179554A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP3954762A1 (en) | 2022-02-16 |
US20220160769A1 (en) | 2022-05-26 |
WO2020197318A1 (en) | 2020-10-01 |
JP2023179554A (en) | 2023-12-19 |
JP2022528086A (en) | 2022-06-08 |
JP2022527932A (en) | 2022-06-07 |
EP3954762A4 (en) | 2023-01-18 |
CN113874492A (en) | 2021-12-31 |
CN113874492B (en) | 2024-03-19 |
KR102298640B1 (en) | 2021-09-07 |
KR20200115357A (en) | 2020-10-07 |
WO2020197319A1 (en) | 2020-10-01 |
CN113874493A (en) | 2021-12-31 |
JP7429713B2 (en) | 2024-02-08 |
KR102298639B1 (en) | 2021-09-07 |
EP3950935A1 (en) | 2022-02-09 |
CN113874493B (en) | 2024-05-10 |
EP3950935A4 (en) | 2023-06-07 |
KR20200115358A (en) | 2020-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220184128A1 (en) | Method for producing car gene-introduced nk cells and use thereof | |
Li et al. | Human iPSC-derived natural killer cells engineered with chimeric antigen receptors enhance anti-tumor activity | |
KR101834687B1 (en) | Novel method for producing differentiated cells | |
JP7058728B2 (en) | Method for producing natural killer cells and their uses | |
CN110603048A (en) | Cytokine combinations | |
JP2021532796A (en) | Protein heterodimer and its use | |
CN116514998B (en) | Chimeric antigen receptor, chimeric antigen receptor-natural killer cell and application thereof in preparation of antitumor drugs | |
CN111356463A (en) | Suicide gene brain tumor therapeutic agent using pluripotent stem cells | |
Xie et al. | Engineering precision therapies: lessons and motivations from the clinic | |
Wang et al. | Pluripotent stem cell-based cell therapies: Current applications and future prospects | |
KR102604208B1 (en) | Method for producing directly reprogrammed natural killer cells and uses thereof | |
JP2023504075A (en) | Method for obtaining CAR-NK cells | |
JP2021069322A (en) | Method for producing cd4-positive regulatory t-cell | |
US20240156963A1 (en) | Combinational immunotherapies using car-m, car-nk, car-eos, and car-n cells | |
CN116286660B (en) | IPSC- (CAR) natural killer cells, preparation method and application thereof in tumor treatment | |
CN113786416B (en) | Use of transgenic NK cells in the treatment of cancer | |
WO2024040138A1 (en) | Universal natural killer cells derived from human pluripotent stem cells and method of use | |
KR20230039789A (en) | Method for producing induced natural killer cells and their use for preventing or treating infectious diseases | |
Zhao et al. | Rapid immune reconstitution and dendritic cell engraftment post–bone marrow transplantation with heterogeneous progenitors and GM-CSF treatment | |
KR20230153301A (en) | Pluripotent Stem Cell-derived Immune Cells Inducing Chemotaxis for Heterogeneous Immune Cells | |
JP2023548382A (en) | Transformed immune cells induce chemotaxis toward xenogeneic immune cells | |
CN113599395A (en) | Pharmaceutical composition for treating cancer containing NK cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY, KOREA, REPUBLIC OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHO, YEE SOOK;KIM, HAN-SEOP;KIM, JAE YUN;AND OTHERS;REEL/FRAME:057655/0255 Effective date: 20210930 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
AS | Assignment |
Owner name: CEFO CO., LTD., KOREA, REPUBLIC OF Free format text: LICENSE;ASSIGNOR:KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY;REEL/FRAME:061624/0364 Effective date: 20221019 |